<SEC-DOCUMENT>0001047469-19-004615.txt : 20190807
<SEC-HEADER>0001047469-19-004615.hdr.sgml : 20190807
<ACCEPTANCE-DATETIME>20190807172947
ACCESSION NUMBER:		0001047469-19-004615
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20190807
DATE AS OF CHANGE:		20190807

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PTC THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001070081
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043416587
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-220151
		FILM NUMBER:		191006577

	BUSINESS ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449
		BUSINESS PHONE:		9082227000

	MAIL ADDRESS:	
		STREET 1:		100 CORPORATE COURT
		CITY:			SOUTH PLAINFIELD
		STATE:			NJ
		ZIP:			07080-2449

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PTC THERAPEUTICS INC
		DATE OF NAME CHANGE:	19980909
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>a2239427z424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg17701_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A NAME="aa17701_filed_pursuant_to_rule__aa101409"> </A>
<A NAME="toc_aa17701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Filed Pursuant to Rule&nbsp;424(b)(5)<BR>  Registration No.&nbsp;333-220151    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> CALCULATION OF REGISTRATION FEE  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="63%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:5pt;text-indent:-5pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Title of each class of securities<BR>
to be registered</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed maximum<BR>
aggregate offering<BR>
price</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount of<BR>
registration fee<SUP>(1)</SUP></B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:4pt;text-indent:-4pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=2>Common Stock, par value $0.001 per share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$125,000,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>$15,150</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:5pt;text-indent:-5pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><SUP>(1)</SUP></FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Calculated
in accordance with Rule&nbsp;457(o) under the Securities Act of 1933, as amended. This "Calculation of Registration Fee" table shall be deemed to update
the "Calculation of Registration Fee" table in the registrant's Registration Statement on Form&nbsp;S-3 (File No.&nbsp;333-220151) in accordance with Rules&nbsp;456(b) and 457(r) under the
Securities Act of 1933, as amended.  </FONT></DD></DL>
<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=507055,FOLIO='blank',FILE='DISK106:[19ZCA1.19ZCA17701]AA17701A.;9',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><B>PROSPECTUS SUPPLEMENT<BR>
(TO PROSPECTUS DATED AUGUST 24, 2017)  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g243370.jpg" ALT="LOGO" WIDTH="180" HEIGHT="93">
  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=4><B>Up to $125,000,000  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=4><B> Common Stock  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="100%" ALIGN="LEFT" >


<P style="font-family:times;"><FONT SIZE=2>We
entered into an At the Market Offering Sales Agreement, or the sales agreement, with Cantor Fitzgerald&nbsp;&amp;&nbsp;Co., or Cantor Fitzgerald, and RBC Capital Markets,&nbsp;LLC, or RBC, on
August&nbsp;7, 2019, relating to the offer and sale from time to time of shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the
terms of the sales agreement, we may offer and sell shares of our common stock, $0.001 par value per share, having an aggregate offering price of up to $125,000,000 from time to time through, at our
option, Cantor Fitzgerald or RBC, acting as a sales agent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our
common stock trades on The Nasdaq Global Select Market under the symbol "PTCT". On August&nbsp;6, 2019, the last sale price of our common stock as reported on The Nasdaq Global Select Market was
$44.75 per share. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Sales
of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made by any method permitted that is deemed to be an "at the market offering" as defined in
Rule&nbsp;415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. We will submit orders to only one sales agent relating to the sale of shares of our common stock
under the sales agreement on any given day. Cantor Fitzgerald and RBC will not be required to sell any specific amount but will act as our sales agents using commercially reasonable efforts to sell on
our behalf all of the shares of common stock requested to be sold by us, consistent with their normal trading and sales practices, on mutually agreed terms between us and Cantor Fitzgerald and RBC.
There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Cantor
Fitzgerald and RBC will be entitled to compensation at a commission rate of up to 3.0% of the gross sales price per share of shares sold by such sales agent under the sales agreement. In
connection with the sale of our common stock on our behalf, each of Cantor Fitzgerald and RBC may be deemed to be an "underwriter" within the meaning of the Securities Act, and the compensation of
Cantor Fitzgerald and RBC will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to Cantor Fitzgerald and RBC with respect to
certain liabilities, including civil liabilities under the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act. See "Plan of Distribution" beginning on
page&nbsp;S-9 of this prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Investing in our common stock involves risk. Please read the information contained in and incorporated by reference under the heading "Risk Factors" beginning on
page&nbsp;S-4 of this prospectus supplement, and under similar headings in the other documents that are filed after the date hereof and incorporated by reference into this prospectus supplement and
accompanying prospectus.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of
this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=5><B>Cantor</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=5>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=5><B>RBC Capital Markets</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2><B>

<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</b></font></p><p align=center style="font-family:times;"><FONT SIZE=2><B>The date of this prospectus supplement is August&nbsp;7, 2019.</B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=626200,FOLIO='blank',FILE='DISK106:[19ZCA1.19ZCA17701]BC17701A.;18',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_bg17701_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="BG17701A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bg17701_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG17701_TOC2"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD COLSPAN=4 ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>PROSPECTUS SUPPLEMENT</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#bi17701_about_this_prospectus_supplement"><p style="font-family:times;margin-top:12pt;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#bi17701_about_this_prospectus_supplement"><FONT SIZE=2><BR>
S-ii</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#bi17701_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#bi17701_special_note_regarding_forward-looking_statements"><FONT SIZE=2>S-iv</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#ca17701_prospectus_supplement_summary"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUPPLEMENT SUMMARY</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ca17701_prospectus_supplement_summary"><FONT SIZE=2>S-1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#cc17701_risk_factors"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc17701_risk_factors"><FONT SIZE=2>S-4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#cc17701_use_of_proceeds"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc17701_use_of_proceeds"><FONT SIZE=2>S-6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#cc17701_dividend_policy"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DIVIDEND POLICY</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc17701_dividend_policy"><FONT SIZE=2>S-7</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#cc17701_dilution"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DILUTION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cc17701_dilution"><FONT SIZE=2>S-8</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#ce1"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce1"><FONT SIZE=2>S-9</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#ce2"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce2"><FONT SIZE=2>S-11</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#ce3"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce3"><FONT SIZE=2>S-11</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#ce4"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce4"><FONT SIZE=2>S-11</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#ce5"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION BY REFERENCE</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ce5"><FONT SIZE=2>S-12</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bg17701_prospectus"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG17701_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#bi17702_about_this_prospectus"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#bi17702_about_this_prospectus"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#da17702_risk_factors"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da17702_risk_factors"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#da17702_where_you_can_find_more_information"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da17702_where_you_can_find_more_information"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#da17702_incorporation_by_reference"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION BY REFERENCE</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da17702_incorporation_by_reference"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#da17702_forward-looking_statements"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da17702_forward-looking_statements"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#da17702_the_company"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>THE COMPANY</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da17702_the_company"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#da17702_consolidated_ratios_of_earnings_to_fixed_charges"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CONSOLIDATED RATIOS OF EARNINGS TO FIXED CHARGES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da17702_consolidated_ratios_of_earnings_to_fixed_charges"><FONT SIZE=2>5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#da17702_use_of_proceeds"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da17702_use_of_proceeds"><FONT SIZE=2>6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#da17702_selling_stockholders"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SELLING STOCKHOLDERS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da17702_selling_stockholders"><FONT SIZE=2>7</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#dc17702_description_of_debt_securities"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF DEBT SECURITIES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc17702_description_of_debt_securities"><FONT SIZE=2>8</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#de17702_description_of_capital_stock"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de17702_description_of_capital_stock"><FONT SIZE=2>17</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#de17702_description_of_depositary_shares"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF DEPOSITARY SHARES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de17702_description_of_depositary_shares"><FONT SIZE=2>22</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#dg17702_description_of_purchase_contracts_and_purchase_units"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF PURCHASE CONTRACTS AND PURCHASE UNITS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg17702_description_of_purchase_contracts_and_purchase_units"><FONT SIZE=2>25</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#dg17702_description_of_warrants"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF WARRANTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg17702_description_of_warrants"><FONT SIZE=2>26</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#dg17702_forms_of_securities"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FORMS OF SECURITIES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg17702_forms_of_securities"><FONT SIZE=2>27</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#dg17702_plan_of_distribution"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg17702_plan_of_distribution"><FONT SIZE=2>29</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#dg17702_legal_matters"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg17702_legal_matters"><FONT SIZE=2>32</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><A HREF="#dg17702_experts"><p style="font-family:times;margin-left:36pt;text-indent:-36pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg17702_experts"><FONT SIZE=2>32</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=106853,FOLIO='S-i',FILE='DISK106:[19ZCA1.19ZCA17701]BG17701A.;14',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_bi17701_1_2"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bi17701_about_this_prospectus_supplement"> </A>
<A NAME="toc_bi17701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS SUPPLEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering and also adds to and updates
information contained in the accompanying prospectus and the documents incorporated by reference herein and therein. The second part, the accompanying prospectus, provides more general information.
Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information contained in this prospectus supplement
and the information contained in the accompanying prospectus or any document incorporated by reference herein or therein filed prior to the date of this prospectus supplement, you should rely on the
information in this prospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date &#151; for example,
a document incorporated by reference in the accompanying prospectus &#151; the statement in the document having the later date modifies or supersedes the earlier statement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for
the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation,
warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not
be relied on as accurately representing the current state of our affairs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
have not and Cantor Fitzgerald&nbsp;&amp;&nbsp;Co., or Cantor Fitzgerald, and RBC Capital Markets,&nbsp;LLC, or RBC, have not authorized anyone to provide any information other than that
contained or incorporated by reference in this prospectus supplement, in the accompanying prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you.
We, Cantor Fitzgerald and RBC take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>This
prospectus supplement and the accompanying prospectus do not constitute an offer to sell, or a solicitation of an offer to purchase, the securities offered by this prospectus supplement and the
accompanying prospectus in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. You should assume that the
information appearing in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein and in any free writing prospectus that we have
authorized for use in connection with this offering is accurate only as of the date of those respective documents. It is important for you to read and consider all information contained in this
prospectus supplement and in the accompanying prospectus, including the documents incorporated by reference herein and therein, in making your investment decision. You should also read and consider
the information in the documents to which we have referred you in the sections entitled "Where You Can Find More Information" and "Incorporation by Reference" in this prospectus supplement and in the
accompanying prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Other
than in the United States, no action has been taken by us, Cantor Fitzgerald or RBC that would permit a public offering of the securities offered by this prospectus in any jurisdiction where
action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or
advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the
applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-ii</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=483063,FOLIO='S-ii',FILE='DISK106:[19ZCA1.19ZCA17701]BI17701A.;15',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<A NAME="page_bi17701_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>about
and to observe any restrictions relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any
securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>Unless
the context otherwise indicates, references in this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein to "PTC," "we," "our,"
"us" and "the Company" refer, collectively, to PTC Therapeutics,&nbsp;Inc., a Delaware corporation, and its consolidated subsidiaries. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-iii</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=945814,FOLIO='S-iii',FILE='DISK106:[19ZCA1.19ZCA17701]BI17701A.;15',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<A NAME="page_bi17701_1_4"> </A>


<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bi17701_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_bi17701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>This prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein include "forward-looking statements"
within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve
substantial risks and uncertainties. All statements, other than statements of historical facts, contained or incorporated by reference in this prospectus supplement or the accompanying prospectus,
including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking
statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and
similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
forward-looking statements in this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein include, among other things, statements
about: </FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to realize the anticipated benefits of our acquisition of Agilis Biotherapeutics,&nbsp;Inc., or Agilis, including the possibility
that the expected impact of benefits from the acquisition, including with respect to the business of Agilis and our expectations with respect to the potential achievement of development, regulatory
and sales milestones and our contingent payments to the former Agilis equityholders with respect thereto, will not be realized or will not be realized within the expected time period, significant
transaction costs, the integration of Agilis's operations and employees into our business, our ability to obtain marketing approval of our gene therapy for the treatment of Aromatic L-Amino Acid
Decarboxylase, or AADC, deficiency, or PTC-AADC, and other product candidates we acquired from Agilis, unknown liabilities, the risk of litigation and/or regulatory actions related to the acquisition,
and other business effects, including the effects of industry, market, economic, political or regulatory conditions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms and processes on a timely basis, or at all,
with third-party payors for Emflaza&#153; (deflazacort) for the treatment of Duchenne muscular dystrophy, or DMD, in the United States and for Translarna&#153; (ataluren) for the
treatment of nonsense mutation DMD, or nmDMD, in the European Economic Area, or EEA, and other countries in which we have or may obtain regulatory approval, or in which there exist significant
reimbursed early access programs, or EAP programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to maintain our marketing authorization of Translarna for the treatment of nmDMD in the EEA (which is subject to the specific
obligation to conduct and submit the results of Study 041 to the European Medicines Agency, or EMA, and annual review and renewal by the European Commission following reassessment of the benefit-risk
balance of the authorization by the EMA); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to enroll, fund, and complete Study 041, a multicenter, randomized, double-blind, 18-month, placebo-controlled clinical trial of
Translarna for the treatment of nmDMD followed by an 18-month open label extension, according to the protocol agreed with the EMA, and by the trial's deadline; </FONT></DD></DL>
</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-iv</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=799570,FOLIO='S-iv',FILE='DISK106:[19ZCA1.19ZCA17701]BI17701A.;15',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<A NAME="page_bi17701_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the anticipated period of market exclusivity for Emflaza for the treatment of DMD in the United States under the Orphan Drug Act of 1983, or
the Orphan Drug Act, the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to complete the United States Food and Drug Adminstration, or FDA, post-marketing requirements to marketing authorization of
Emflaza; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to complete any dystrophin study necessary in order to resolve the matters set forth in the FDA's denial of our appeal to the
Complete Response Letter we received from the FDA in connection with our New Drug Application, or NDA, for Translarna for the treatment of nmDMD, and our ability to perform additional clinical trials,
non-clinical studies or CMC assessments or analyses at significant cost; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing and scope of our continued commercialization of Translarna as a treatment for nmDMD in the EEA or other territories outside of the
United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to obtain additional and maintain existing reimbursed named patient and cohort EAP programs for Translarna for the treatment of
nmDMD on adequate terms, or at all; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations and the potential financial impact and benefits related to our Collaboration and Licensing Agreement with Akcea
Therapeutics,&nbsp;Inc., or Akcea, including with respect to the timing of regulatory approval of Tegsedi<SUP>TM</SUP> (inotersen) and Waylivra<SUP>TM</SUP> (volanesorsen) in countries in
which we are licensed to commercialize them, the potential commercialization of Tegsedi and Waylivra, and our expectations with respect to contingent payments to Akcea based on the potential
achievement of certain regulatory milestones and royalty payments by us to Akcea based on our potential achievement of certain net sales thresholds; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our estimates regarding the potential market opportunity for Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra, risdiplam or any other product
candidate, including the size of eligible patient populations and our ability to identify such patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our estimates regarding expenses, future revenues, third-party discounts and rebates, capital requirements and needs for additional financing,
including our ability to maintain the level of our expenses consistent with our internal budgets and forecasts and to secure additional funds on favorable terms or at all; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing and conduct of our ongoing, planned and potential future clinical trials and studies of Translarna for the treatment of nmDMD,
aniridia, and Dravet syndrome/CDKL5, each caused by nonsense mutations, and Emflaza for the treatment of limb-girdle&nbsp;2I, as well as studies in gene therapy, splicing and oncology programs,
including the timing of initiation, enrollment and completion of the trials and the period during which the results of the trials will become available; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the rate and degree of market acceptance and clinical utility of Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra and risdiplam; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the ability and willingness of patients and healthcare professionals to access Translarna through alternative means if pricing and
reimbursement negotiations in the applicable territory do not have a positive outcome; </FONT></DD></DL>
</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-v</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=509747,FOLIO='S-v',FILE='DISK106:[19ZCA1.19ZCA17701]BI17701A.;15',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<A NAME="page_bi17701_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the timing of, and our ability to obtain additional marketing authorizations for, Translarna, Tegsedi and our other product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the ability of Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra and risdiplam and our other product candidates to meet existing or future
regulatory standards; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to maintain the current labeling under the marketing authorization in the EEA or expand the approved product label of Translarna
for the treatment of nmDMD in non-ambulatory patients or otherwise; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the potential receipt of revenues from future sales of Translarna, Emflaza and other product candidates, including our ability to earn a profit
from sales or licenses of Translarna for the treatment of nmDMD in the countries in which we have or may obtain regulatory approval and of Emflaza for the treatment of DMD in the United States; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the potential impact that enrollment, funding and completion of Study 041 may have on our revenue growth; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our sales, marketing and distribution capabilities and strategy, including the ability of our third-party manufacturers to manufacture and
deliver Translarna and Emflaza in clinically and commercially sufficient quantities and the ability of distributors to process orders in a timely manner and satisfy their other obligations to us; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to establish and maintain arrangements for the manufacture of Translarna, Emflaza and our other product candidates that are
sufficient to meet clinical trial and commercial launch requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to increase our manufacturing capabilities for our gene therapy platform; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations with respect to the potential financial impact of our leased biologics facility and our ability to satisfy our obligations
under the terms of the lease agreement for such facility; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to satisfy our obligations under the terms of the credit and security agreement with MidCap Financial Trust, or MidCap Financial,
as administrative agent and MidCap Financial and certain other financial institutions as lenders thereunder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our other regulatory submissions, including with respect to timing and outcome of regulatory review; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our plans to pursue development of Translarna and Emflaza for additional indications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to advance our earlier stage programs and pursue research and development of other product candidates, including our splicing, gene
therapy and oncology programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether we may pursue business development opportunities, including potential collaborations, alliances, and acquisition or licensing of assets
and our ability to successfully develop or commercialize any assets to which we may gain rights pursuant to such business development opportunities; </FONT></DD></DL>
</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-vi</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=8,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=286127,FOLIO='S-vi',FILE='DISK106:[19ZCA1.19ZCA17701]BI17701A.;15',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<A NAME="page_bi17701_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the potential advantages of Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra and ridisplam and any other product candidate; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our intellectual property position; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the impact of government laws and regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the impact of litigation that has been or may be brought against us or of litigation that we are pursuing against others; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our competitive position; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations with respect to the development and regulatory status of our product candidates and program directed against spinal muscular
atrophy in collaboration with F.&nbsp;Hoffmann La Roche&nbsp;Ltd and Hoffmann La Roche&nbsp;Inc., which we refer to collectively as Roche, and the Spinal Muscular Atrophy Foundation, or the SMA
Foundation, and our estimates regarding future revenues from achievement of milestones in that program; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations related to the use of proceeds from this offering. </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>We
may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results
or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements
included in this prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein, particularly in the "Risk Factors" section of this prospectus
supplement and the "Risk Factors" section of our <A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008119000018/ptct1231201810-k.htm">Annual Report on Form&nbsp;10-K for the
year ended December&nbsp;31, 2018</A> that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking
statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make. We do not assume any obligation to update any
forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-vii</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=9,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=455740,FOLIO='S-vii',FILE='DISK106:[19ZCA1.19ZCA17701]BI17701A.;15',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ca17701_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border-top:#000000 solid 1.0pt;border-bottom:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca17701_prospectus_supplement_summary"> </A>
<A NAME="toc_ca17701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUPPLEMENT SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>This summary highlights selected information contained elsewhere in this prospectus supplement and the accompanying prospectus and in
the documents we incorporate by
reference. This summary does not contain all of the information you should consider before making an investment decision. You should read this entire prospectus supplement and the accompanying
prospectus carefully, especially the risks of investing in our common stock discussed under "Risk Factors" beginning on page&nbsp;S-4 of this prospectus supplement and the "Risk Factors" section of
our <A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008119000018/ptct1231201810-k.htm">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2018</A>, along with our consolidated financial statements and notes to those consolidated financial statements and the other information incorporated by reference in this prospectus
supplement and the accompanying prospectus and in our filings with the Securities and Exchange Commission, or the SEC.</I></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


PTC Therapeutics,&nbsp;Inc.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We are a science-led global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that
provide benefits to patients with rare disorders. Our ability to globally commercialize products is the foundation that drives our continued investment in a robust pipeline of transformative medicines
and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. Our strategy is to bring best-in-class therapies with differentiated clinical benefit to
patients affected by rare disorders and to leverage our global commercial infrastructure to maximize value for our patients and other stakeholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Company Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We were incorporated under the laws of the State of Delaware on March&nbsp;31, 1998, under the name PTC Therapeutics,&nbsp;Inc. Our principal executive
offices are located at 100 Corporate Court, South Plainfield, New Jersey 07080. Our telephone number is (908)&nbsp;222-7000. We maintain a website at </FONT> <FONT SIZE=2><I>www.ptcbio.com</I></FONT><FONT SIZE=2>. The information contained on, or
that can be accessed through, our website is not a part of this prospectus supplement or the
accompanying prospectus. We have included our website address in this prospectus supplement and the accompanying prospectus solely as an inactive textual reference. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=10,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=177211,FOLIO='S-1',FILE='DISK106:[19ZCA1.19ZCA17701]CA17701A.;14',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<A NAME="page_ca17701_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border-top:#000000 solid 1.0pt;border-bottom:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca17701_the_offering"> </A>
<A NAME="toc_ca17701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  THE OFFERING    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="233pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock offered by us</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Shares of our common stock having an aggregate offering price of up to $125,000,000.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock to be outstanding after this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Up to 2,793,296 shares, assuming sales at a price of $44.75 per share, which was the closing price of our common stock on
The Nasdaq Global Select Market on August&nbsp;6, 2019, and an aggregate offering price of $125,000,000. The actual number of shares issued will vary depending on the sales price under this offering. In addition, as there is no minimum offering
amount required as a condition to close this offering, the actual number of shares that may be sold is not determinable at this time. See "Dilution" beginning on page&nbsp;S-8 of this prospectus supplement.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Manner of Offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>"At the market offering" that may be made from time to time through, at our option, either of our sales agents, Cantor
Fitzgerald&nbsp;&amp;&nbsp;Co. and RBC Capital Markets,&nbsp;LLC. See "Plan of Distribution" beginning on page&nbsp;S-9 of this prospectus supplement.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of proceeds</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We intend to use the net proceeds from this offering for working capital and other general corporate purposes. General
corporate purposes may include research and development, manufacturing and commercialization expenditures, repayment and refinancing of debt, other capital expenditures and further strategic transactions to expand and diversify our product pipeline,
including through the acquisition of assets, businesses, rights to products, product candidates or technologies or through strategic alliances or collaborations.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>See "Use of Proceeds" beginning on page&nbsp;S-6 of this prospectus supplement for more information.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>You should read the "Risk Factors" section of this prospectus supplement, as well as those risk factors that are
incorporated by reference in this prospectus supplement and the accompanying prospectus, for a discussion of factors to consider carefully before deciding to purchase shares of our common stock.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nasdaq Global Select Market symbol</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PTCT</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>The
number of shares of our common stock to be outstanding after this offering is based on 58,947,256 shares of our common stock outstanding as of July&nbsp;31, 2019. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
number of shares of our common stock to be outstanding after this offering excludes:</FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 10,689,944 shares of our common stock issuable upon the exercise of outstanding stock options as of July&nbsp;31, 2019 at a weighted-average
exercise price of $30.65 per share; </FONT></DD></DL>
</UL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=11,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=658599,FOLIO='S-2',FILE='DISK106:[19ZCA1.19ZCA17701]CA17701A.;14',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<A NAME="page_ca17701_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border-top:#000000 solid 1.0pt;border-bottom:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 555,683 shares of our common stock issuable upon the vesting of outstanding restricted stock units as of July&nbsp;31, 2019; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 437,110 of our common stock reserved for future issuance under our 2013 Long Term Incentive Plan as of July&nbsp;31, 2019; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 536,329 shares of our common stock reserved for future issuance under our Employee Stock Purchase Plan as of July&nbsp;31, 2019; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 7,160 shares of our common stock issuable upon the exercise of warrants outstanding as of July&nbsp;31, 2019, at a weighted-average exercise
price of $171.43 per share; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the shares of our common stock reserved for issuance upon conversion of our 3.00% convertible senior notes due August&nbsp;12, 2022. </FONT></DD></DL>
</UL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=12,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=49242,FOLIO='S-3',FILE='DISK106:[19ZCA1.19ZCA17701]CA17701A.;14',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_cc17701_1_4"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc17701_risk_factors"> </A>
<A NAME="toc_cc17701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>Investing in our common stock involves significant risks. In deciding whether to invest, and in consultation with your own financial
and legal advisors, you should carefully consider the following risk factors and the risks described in the "Risk Factors" section of our
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008119000018/ptct1231201810-k.htm">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2018</A>, as well as the other information contained in this prospectus supplement, the accompanying prospectus and in our filings with the Securities and Exchange Commission, or the SEC,
that we have incorporated by reference in this prospectus supplement and the accompanying prospectus. Any of these risks could have a material adverse effect on our business, financial condition,
results of operations and prospects and cause the value of our stock to decline, which could cause you to lose all or part of your investment. The risks and uncertainties we have described are not the
only ones facing our company. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business operations.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to this Offering  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our management may invest or spend the proceeds of this offering in ways with which you may not agree or in
ways which may not yield a significant return, if any.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our management will have broad discretion over the use of the net proceeds from this offering and could use them for purposes other than those contemplated at
the time of this offering. You may not agree with the manner in which our management chooses to allocate and spend these net proceeds. You will not have the opportunity, as part of your investment
decision, to assess whether the net proceeds are being used appropriately. The net proceeds may be used for corporate purposes that do not increase our operating results or market value. Until the net
proceeds are used, they may be placed in investments that do not produce significant income or investments that lose value. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


You will suffer immediate dilution of your investment.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The public offering price of our common stock will be substantially higher than the net tangible book value per share of our common stock. Therefore, if you
purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our net tangible book value per share after this offering. To the extent outstanding
options or warrants are exercised or shares of our common stock are issued upon the vesting of restricted stock units or upon the conversion of our 3.00% convertible senior notes due August&nbsp;12,
2022, you will incur further dilution. Assuming that an aggregate of 2,793,296 shares of our common stock are sold at a price of $44.75 per share pursuant to this prospectus supplement, which was the
last sale price of our common stock as reported on The Nasdaq Global Select Market on August&nbsp;6, 2019, for an aggregate offering price of approximately $125,000,000 in this offering, and after
deducting estimated commissions and estimated aggregate offering expenses payable by us, you would experience immediate dilution of $34.82 per share, representing the difference between our as
adjusted net tangible book value per share as of June&nbsp;30, 2019 after giving effect to this offering and the assumed public offering price. See "Dilution." </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


You may experience future dilution as a result of future offerings.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or exchangeable
for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is less than the
price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which
we may sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors
in this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=911571,FOLIO='S-4',FILE='DISK106:[19ZCA1.19ZCA17701]CC17701A.;14',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<A NAME="page_cc17701_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future,
capital appreciation, if any, will be our stockholders' sole source of gain.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the
development and growth of our business. In addition, the terms of our existing credit and security agreement with MidCap Financial Trust preclude us, and the terms of any future debt agreements may
preclude us, from paying dividends without lender consent. As a result, capital appreciation, if any, of our common stock will be our stockholders' sole source of gain for the foreseeable future. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Future sales of shares of our common stock, including by us or our directors and executive officers, could
cause the market price of our common stock to drop significantly, even if our business is doing well.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>A substantial portion of our outstanding common stock is freely tradeable. Some of these shares are currently "restricted" securities as a result of
securities laws, but are able to be sold, subject to any applicable volume limitations under federal securities laws with respect to affiliate sales. As such, sales of a substantial number of shares
of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, by us or others,
could reduce the market price of our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
have issued a significant number of equity awards under our equity compensation plans or as inducement grants to new hire employees pursuant to Nasdaq rules. The shares underlying these awards are
or, with respect to certain option grants, have been or will be registered on a Form&nbsp;S-8 registration statement. As a result, upon vesting these shares can be freely exercised and sold in the
public market upon issuance, subject to volume limitations applicable to affiliates. The exercise of options or warrants and the subsequent sale of the underlying common stock or the sale of
restricted stock upon vesting could cause a decline in our stock price. These sales also might make it difficult for us to sell equity securities in the future at a time and at a price that we deem
appropriate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Certain
of our employees, executive officers and directors have entered or may enter into Rule&nbsp;10b5-1 plans providing for sales of shares of our common stock from time to time. Under a
Rule&nbsp;10b5-1 plan, a broker executes trades pursuant to parameters established by the employee, director or officer when entering into the plan, without further direction from the employee,
officer or director. A Rule&nbsp;10b5-1 plan may be amended or terminated in some circumstances. Our employees, executive officers and directors may also buy or sell additional shares outside of a
Rule&nbsp;10b5-1 plan when they are not in possession of material, nonpublic information. As of July&nbsp;31, 2019, an aggregate of 123,594 shares of our common stock, including shares of our
common stock underlying stock option awards, held by our executive officers were subject to a Rule&nbsp;10b5-1 plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>In
connection with our acquisition of Emflaza, we issued an affiliate of Marathon Pharmaceuticals,&nbsp;LLC, or Marathon, 6,683,598 shares of our common stock. In addition, in connection with our
acquisition of Agilis Biotherapeutics,&nbsp;Inc., or Agilis, we issued Agilis equityholders 3,500,907 shares of our common stock. These shares are able to be freely sold in the public market subject
to any requirements or restrictions, including any applicable volume limitations, imposed by Rule&nbsp;144 under the Securities Act. The sale or resale of these shares in the public market, or the
market's expectation of such sales, may result in an immediate and substantial decline in our stock price. Such a decline will adversely affect our investors and also might make it difficult for us to
sell equity securities in the future at a time and at a price that we deem appropriate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
have a significant number of shares that are subject to outstanding options and warrants. The exercise of these options and warrants and the subsequent sale of the underlying common stock could
cause a further decline in our stock price. These sales also might make it difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=14,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=1032674,FOLIO='S-5',FILE='DISK106:[19ZCA1.19ZCA17701]CC17701A.;14',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<A NAME="page_cc17701_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc17701_use_of_proceeds"> </A>
<A NAME="toc_cc17701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We may issue and sell shares of our common stock having an aggregate offering price of up to $125,000,000 from time to time. Because there is no minimum
offering amount required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
intend to use the net proceeds from this offering for working capital and other general corporate purposes. General corporate purposes may include research and development, manufacturing and
commercialization expenditures, repayment and refinancing of debt, capital expenditures and further strategic transactions to expand and diversify our product pipeline, including through the
acquisition of assets, businesses, rights to products, product candidates or technologies or through strategic alliances or collaborations. We have not determined the amount of net proceeds to be used
specifically for such purposes. As a result, management will retain broad discretion over the allocation of the net proceeds. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>This
expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business
conditions evolve. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the progress of our development, manufacturing and
commercialization efforts, the status of and results from clinical trials and studies, the timing of regulatory submissions and the outcome of regulatory reviews, as well as any collaborations that we
may enter into with third parties for our product candidates, and any unforeseen cash needs. We have no current agreements or commitments for any material acquisition of assets, businesses, rights to
products, product candidates or technologies or any material strategic alliances or collaborations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Pending
our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment grade, interest bearing
instruments and U.S. government securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=15,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=68675,FOLIO='S-6',FILE='DISK106:[19ZCA1.19ZCA17701]CC17701A.;14',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<A NAME="page_cc17701_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc17701_dividend_policy"> </A>
<A NAME="toc_cc17701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  DIVIDEND POLICY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We have never declared or paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and
development of our business. We do not intend to pay cash dividends to holders of our common stock in the foreseeable future. In addition, the terms of our existing credit and security agreement with
MidCap Financial Trust preclude us from paying cash dividends without MidCap Financial Trust's consent. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=16,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=676734,FOLIO='S-7',FILE='DISK106:[19ZCA1.19ZCA17701]CC17701A.;14',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<A NAME="page_cc17701_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="cc17701_dilution"> </A>
<A NAME="toc_cc17701_4"> </A>
<BR></FONT><FONT SIZE=2><B>  DILUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the public
offering price per share of our common stock and the as adjusted net tangible book value per share of our common stock after this offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Our
historical net tangible book value as of June&nbsp;30, 2019 was $488.7&nbsp;million, or $8.32 per share of our common stock. Historical net tangible book value per share represents the amount
of our total tangible assets less total liabilities, divided by the number of shares of our common stock outstanding. After giving effect to the assumed sale by us of shares of our common stock having
an aggregate offering price of $125,000,000 at an assumed public offering price of $44.75 per share, which was the last reported sale price of our common stock on The Nasdaq Global Select Market on
August&nbsp;6, 2019, and after deducting estimated commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of June&nbsp;30, 2019 would have been
$610.8&nbsp;million, or $9.93 per share. This represents an immediate increase in net tangible book value per share of $1.61 to existing stockholders and immediate dilution of $34.82 in net tangible
book value per share to new investors purchasing common stock in this offering. Dilution per share to new investors is determined by subtracting as adjusted net tangible book value per share after
this offering from the public offering price per share paid by new investors. The following table illustrates this dilution on a per share basis. The as adjusted information is illustrative only and
will adjust based on the actual price to the public, the actual number of shares sold and other terms of the offering determined at the time shares of our common stock are sold pursuant to this
prospectus supplement. The shares sold in this offering, if any, will be sold from time to time at various prices. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assumed public offering price per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>44.75</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Historical net tangible book value per share as of June&nbsp;30, 2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase in net tangible book value per share attributable to shares of common stock to be issued in this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.61</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>As adjusted net tangible book value per share after this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9.93 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution per share to new investors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34.82 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>The
foregoing table and calculations are based on actual shares of our common stock outstanding as of June&nbsp;30, 2019 and exclude as of such date:</FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 10,853,301 shares of our common stock issuable upon the exercise of outstanding stock options at a weighted-average exercise price of $30.07
per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 560,921 shares of our common stock issuable upon the vesting of outstanding restricted stock units; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 302,538 additional shares of our common stock reserved for future issuance under our 2013 Long Term Incentive Plan; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 536,329 shares of our common stock reserved for future issuance under our Employee Stock Purchase Plan; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 7,160 shares of our common stock issuable upon the exercise of outstanding warrants at a weighted-average exercise price of $171.43 per share;
and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the shares of our common stock reserved for issuance upon conversion of our 3.00% convertible senior notes due August&nbsp;12, 2022. </FONT></DD></DL>
</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=17,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=606414,FOLIO='S-8',FILE='DISK106:[19ZCA1.19ZCA17701]CC17701A.;14',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ce17701_1_9"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="ce1"></A>PLAN OF DISTRIBUTION  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We have entered into an At the Market Offering Sales Agreement, or the sales agreement, with Cantor Fitzgerald&nbsp;&amp;&nbsp;Co., or Cantor Fitzgerald, and
RBC Capital Markets,&nbsp;LLC, or RBC, under which we may offer and sell shares of our common stock having an aggregate offering price of up to $125,000,000 from time to time through, at our option,
Cantor Fitzgerald or RBC, acting as sales agent. The sales agreement has been filed as an exhibit to a Current Report on Form&nbsp;8-K. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We
will submit orders to only one sales agent relating to the sale of shares of our common stock under the sales agreement on any given day. Upon delivery of a placement notice to a sales agent and
subject to the terms and conditions of the sales agreement, such sales agent may offer and sell shares of our common stock by any method permitted by law deemed to be an "at the market offering," as
defined in Rule&nbsp;415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. We may instruct such sales agent not to sell common stock if the sales cannot be
effected at or above the
price designated by us from time to time. We or the sales agents may suspend the offering of common stock upon notice and subject to other conditions. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>We
will pay the sales agents commissions for their services in acting as agent in the sale of our common stock. A sales agent is entitled to compensation at a commission rate of up to 3.0% of the
gross sales price per share sold by such sales agent under the sales agreement. Because there is no minimum offering amount required as a condition to close this offering, the actual total public
offering amount, commissions and proceeds to us, if any, are not determinable at this time. We estimate that the total expenses for the offering, excluding compensation and reimbursements, if any,
payable to Cantor Fitzgerald and RBC under the terms of the sales agreement, will be approximately $0.5&nbsp;million. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Settlement
for sales of shares of common stock will occur on the second business day following the date on which any sales are made, or on some other date that is agreed upon by us and the applicable
sales agent in connection with a particular transaction, in return for payment of the net proceeds to us. Sales of our common stock as contemplated in this prospectus supplement will be settled
through the facilities of The Depository Trust Company or by such other means as we and the applicable sales agents may agree upon. There is no arrangement for funds to be received in an escrow, trust
or similar arrangement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
sales agents will use their commercially reasonable efforts, consistent with their sales and trading practices, to solicit offers to purchase the shares of common stock under the terms and subject
to the conditions set forth in the sales agreement. In connection with the sale of the shares of common stock on our behalf, the applicable sales agent may be deemed to be an "underwriter" within the
meaning of the Securities Act, and the compensation of such sales agent (and their respective partners, members, directors, officers, employees and agents) may be deemed to be underwriting commissions
or discounts. We have agreed to provide indemnification and contribution to each sales agent against certain liabilities, including civil liabilities under the Securities Act. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
offering of shares of our common stock pursuant to the sales agreement will terminate upon the termination of the sales agreement as permitted therein. Either sales agent may terminate the sales
agreement, with respect to such sales agent's rights and obligations under the sales agreement, at any time upon ten days' prior notice. We may terminate the sales agreement with respect to either or
both sales agents at any time upon ten days' prior notice (or three days' prior notice in the event there is no placement notice in effect). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>The
sales agents and their respective affiliates may in the future provide various investment banking, commercial banking and other financial services for us, our subsidiaries and our affiliates, for
which </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=18,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=1007539,FOLIO='S-9',FILE='DISK106:[19ZCA1.19ZCA17701]CE17701A.;17',USER='WWASSER',CD=';7-AUG-2019;16:09' -->
<A NAME="page_ce17701_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>services
they may in the future receive customary fees. To the extent required by Regulation&nbsp;M, the sales agents will not engage in any market-making activities involving our common stock while
the offering is ongoing under this prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>This
prospectus supplement and the accompanying prospectus in electronic format may be made available on a website maintained by Cantor Fitzgerald or RBC, and each of Cantor Fitzgerald and RBC may
distribute this prospectus supplement and the accompanying prospectus electronically. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=19,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=873766,FOLIO='S-10',FILE='DISK106:[19ZCA1.19ZCA17701]CE17701A.;17',USER='WWASSER',CD=';7-AUG-2019;16:09' -->
<A NAME="page_ce17701_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="ce2"></A>LEGAL MATTERS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The validity of the shares of common stock offered hereby will be passed upon for us by Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP, New York, New York.
Cantor Fitzgerald&nbsp;&amp;&nbsp;Co. and RBC Capital Markets,&nbsp;LLC are being represented in connection with this offering by Davis Polk&nbsp;&amp; Wardwell&nbsp;LLP, New York, New York. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="ce3"></A>EXPERTS  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008119000018/ptct1231201810-k.htm">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31,
2018</A>, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2018, as set forth in their reports, which are incorporated by reference in this
prospectus supplement and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young&nbsp;LLP's reports, given on their
authority as experts in accounting and auditing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The
financial statements of Agilis Biotherapeutics,&nbsp;Inc. as of and for the years ended December&nbsp;31, 2017 and 2016, incorporated in this prospectus by reference from our
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008118000066/form8-k082418.htm">Current Report on Form&nbsp;8-K filed August&nbsp;24, 2018</A> have been audited
by BDO USA,&nbsp;LLP, independent auditors, as stated in their report, which is incorporated herein by reference. Such financial statements have been so incorporated in reliance upon the report of
such firm given upon their authority as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="ce4"></A>WHERE YOU CAN FIND MORE INFORMATION  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the
Internet at the SEC's website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at http://www.ptcbio.com. Our website is not a part of
this prospectus supplement and accompanying prospectus and is not incorporated by reference in this prospectus supplement. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>This
prospectus supplement is part of a registration statement we filed with the SEC. This prospectus supplement and the accompanying prospectus omit some information contained in the registration
statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information on us and our consolidated subsidiaries and
the securities we are offering. Statements in this prospectus supplement and the accompanying prospectus concerning any document we filed as an exhibit to the registration statement or that we
otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to these filings. You should review the complete document to evaluate these statements. You can obtain
a copy of the registration statement from the SEC at the address listed above or from the SEC's Internet site. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=20,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=976712,FOLIO='S-11',FILE='DISK106:[19ZCA1.19ZCA17701]CE17701A.;17',USER='WWASSER',CD=';7-AUG-2019;16:09' -->
<A NAME="page_ce17701_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="ce5"></A>INCORPORATION BY REFERENCE  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can disclose important information to you by
referring you to those publicly available documents. The information that we incorporate by reference in this
prospectus supplement and the accompanying prospectus is considered to be part of this prospectus supplement and the accompanying prospectus. Because we are incorporating by reference future filings
with the SEC, this prospectus supplement and the accompanying prospectus are continually updated and those future filings may modify or supersede some of the information included or incorporated in
this prospectus supplement and the accompanying prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this
prospectus supplement, the accompanying prospectus or in any document previously incorporated by reference have been modified or superseded. This prospectus supplement and the accompanying prospectus
incorporate by reference the documents listed below (File No.&nbsp;001-35969) and any future filings we make with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Securities Exchange
Act of 1934, as amended (in each case, other than those documents or the portions of those documents not deemed to be filed), until the offering of the securities offered hereby is terminated or
completed:</FONT></P>

<UL>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008119000018/ptct1231201810-k.htm">Annual Report on Form&nbsp;10-K
for the fiscal year ended December&nbsp;31, 2018;</A></FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the information specifically incorporated by reference into our
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008119000018/ptct1231201810-k.htm">Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31,
2018</A> from our <A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008119000023/ptct2019proxy.htm">definitive proxy statement for the 2019 Annual Meeting of
Shareholders, filed on April&nbsp;25, 2019;</A></FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008119000028/ptct0331201910-q.htm">Quarterly Reports on
Form&nbsp;10-Q for the fiscal quarters ended March&nbsp;31, 2019</A> and
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008119000050/ptct0630201910-q.htm">June&nbsp;30, 2019;</A></FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Current Reports on Form&nbsp;8-K filed on
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008118000066/form8-k082418.htm">August&nbsp;24, 2018</A> (solely with respect to Item&nbsp;9.01 and
Exhibits&nbsp;23.1, 99.3 and 99.4), <A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000110465919003422/a19-3421_18k.htm">January&nbsp;25, 2019</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008119000030/a8-k6319.htm">June&nbsp;3, 2019</A> (excluding Item&nbsp;7.01 and Exhibit&nbsp;99.1),
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008119000038/a8-k061219.htm">June&nbsp;13, 2019</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008119000046/a8-k080519.htm">August&nbsp;5, 2019</A> (excluding Item&nbsp;7.01 and Exhibit&nbsp;99.1) and
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000141057819000703/0001410578-19-000703-index.htm">August&nbsp;7, 2019</A>; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000110465913049330/a13-6876_78a12b.htm">the description of the securities
contained in our registration statement on Form&nbsp;8-A filed on June&nbsp;14, 2013, including any amendment or report filed for the purpose of updating such description.</A> </FONT></DD></DL>
</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>You
may request a copy of these filings, at no cost, by writing or telephoning us at the following address or phone number: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>PTC
Therapeutics,&nbsp;Inc.<BR>
100 Corporate Court<BR>
South Plainfield, New Jersey 07080<BR>
(908)&nbsp;222-7000<BR>
Attention: Investor Relations </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=21,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=971153,FOLIO='S-12',FILE='DISK106:[19ZCA1.19ZCA17701]CE17701A.;17',USER='WWASSER',CD=';7-AUG-2019;16:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><B>PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g337856.jpg" ALT="LOGO" WIDTH="169" HEIGHT="81">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>PTC Therapeutics,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Debt Securities<BR>
Common Stock<BR>
Preferred Stock<BR>
Depositary Shares<BR>
Purchase Contracts<BR>
Purchase Units<BR>
Warrants  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue securities from time to time in one or more offerings. This prospectus describes the general terms of these securities and the
general manner in which these securities will be offered. We will provide the specific terms of these securities in supplements to this prospectus. The prospectus supplements will also describe the
specific manner in which these securities will be offered and may also supplement, update or amend information contained in this document. This prospectus may be used to offer shares of our common
stock for the account of persons other than us, whom we refer to in this prospectus as "selling stockholders." You should read this prospectus and any applicable prospectus supplement carefully before
you invest. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
or any selling stockholders may offer these securities in amounts, at prices and on terms determined at the time of offering. The securities may be sold directly to you, through
agents, or through underwriters and dealers. If agents, underwriters or dealers are used to sell the securities, we will name them and describe their compensation in a prospectus supplement. Unless
otherwise set forth in a prospectus supplement, we will not receive any proceeds from the sale of common stock by any selling stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock is listed on The NASDAQ Global Select Market under the symbol "PTCT." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=3><B>Investing in these securities involves significant risks. See the information contained in this prospectus under the heading "Risk Factors"
beginning on page&nbsp;2, in any accompanying prospectus supplement and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider
before deciding to purchase these securities.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2><B>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</b></font></p><p align=center style="font-family:times;"><font></FONT><FONT SIZE=2><B>The date of this prospectus is August&nbsp;24, 2017.</B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=22,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=305254,FOLIO='blank',FILE='DISK108:[19ZCA2.19ZCA17702]BC17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="BG17702A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bg17702_table_of_contents"> </A>
<A NAME="toc_bg17702_1"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="23pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION BY REFERENCE</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FORWARD-LOOKING STATEMENTS</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>THE COMPANY</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CONSOLIDATED RATIOS OF EARNINGS TO FIXED CHARGES</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SELLING STOCKHOLDERS</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF DEBT SECURITIES</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF CAPITAL STOCK</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF DEPOSITARY SHARES</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF PURCHASE CONTRACTS AND PURCHASE UNITS</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF WARRANTS</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FORMS OF SECURITIES</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
29</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=23,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=513094,FOLIO='blank',FILE='DISK108:[19ZCA2.19ZCA17702]BG17702A.;6',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_bi17702_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="ATP"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bi17702_about_this_prospectus"> </A>
<A NAME="toc_bi17702_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, which we refer to as the SEC,
utilizing a "shelf" registration process. Under this shelf registration process, we may from time to time sell any combination of the securities described in this prospectus in one or more offerings,
and selling stockholders may from time to time sell shares of common stock described in this prospectus in one or more offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus provides you with a general description of the securities we or selling stockholders may offer. Each time we or selling stockholders sell securities, we will provide one
or more prospectus supplements that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information contained in this
prospectus. You should read both this prospectus and the accompanying prospectus supplement together with the additional information described under the heading "Where You Can Find More Information"
beginning on page&nbsp;2 of this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not authorized anyone to provide you with information different from that contained in this prospectus, any accompanying prospectus supplement or in any related free writing
prospectus filed by us with the SEC. We do not take any responsibility for, and cannot provide any assurance as to the reliability of, any information other than the information in this prospectus,
any accompanying prospectus supplement or in any related free writing prospectus filed by us with the SEC. This prospectus and the accompanying prospectus supplement do not constitute an offer to sell
or the
solicitation of an offer to buy any securities other than the securities described in the accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities
in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by
reference and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially
since those dates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
the context otherwise indicates, references in this prospectus to "PTC," "we," "our," "us" and "the Company" refer, collectively, to PTC Therapeutics,&nbsp;Inc., a Delaware
corporation, and its consolidated subsidiaries. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=24,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=343312,FOLIO='1',FILE='DISK108:[19ZCA2.19ZCA17702]BI17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_da17702_1_2"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="RF"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da17702_risk_factors"> </A>
<A NAME="toc_da17702_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investing in our securities involves significant risks. You should carefully consider the risks and uncertainties described in this prospectus
and any accompanying prospectus supplement, including the risk factors set forth in our filings with the SEC that are incorporated by reference herein, before making an investment decision pursuant to
this prospectus and any accompanying prospectus supplement relating to a specific offering. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
business, financial condition and results of operations could be materially and adversely affected by any or all of these risks or by additional risks and uncertainties not presently
known to us or that we currently deem immaterial that may adversely affect us in the future. <A NAME="WYCF"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da17702_where_you_can_find_more_information"> </A>
<A NAME="toc_da17702_2"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public
over the Internet at the SEC's website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available
on our website at http://www.ptcbio.com. Our website is not a part of this prospectus and is not incorporated by reference in this prospectus. You may also read and copy any document we file at the
SEC's Public Reference Room, 100&nbsp;F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the Public Reference Room. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus is part of a registration statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance with SEC rules and
regulations. You should review the information and exhibits in the registration statement for further information on us and our consolidated subsidiaries and the securities we are offering. Statements
in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by
reference to these filings. You should review the complete document to evaluate these statements. You can obtain a copy of the registration statement from the SEC at the address listed above or from
the SEC's website. <A NAME="IBR"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da17702_incorporation_by_reference"> </A>
<A NAME="toc_da17702_3"> </A>
<BR></FONT><FONT SIZE=2><B>  INCORPORATION BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to incorporate by reference in this prospectus much of the information we file with the SEC, which means that we can disclose
important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus.
Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated and those future filings may modify or supersede some of the information included or
incorporated in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any document
previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents listed below (File No.&nbsp;001-35969) and any future filings we make
with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act (in each case, other than those documents or the portions of those
documents not deemed to be filed) until the offering of the securities under the registration statement is terminated or completed:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008117000062/ptct1231201610-k.htm">Annual Report on Form&nbsp;10-K
for the fiscal year ended December&nbsp;31, 2016,</A> including the information specifically incorporated by reference into the Annual Report on Form&nbsp;10-K from our
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008117000077/ptctproxy4282017.htm">definitive proxy statement for the 2017 Annual Meeting of
Stockholders;</A></FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Quarterly Reports on Form&nbsp;10-Q for the fiscal quarters ended
<A HREF="http://www.sec.gov/Archives/edgar/data/1235010/000123501017000012/mnta1q201710-q.htm">March&nbsp;31, 2017</A> and
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008117000117/ptct0630201710-q.htm">June&nbsp;30, 2017</A>; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=25,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=988355,FOLIO='2',FILE='DISK108:[19ZCA2.19ZCA17702]DA17702A.;10',USER='NDEWIND',CD=';7-AUG-2019;16:19' -->
<A NAME="page_da17702_1_3"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Current Reports on Form&nbsp;8-K filed on
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008117000055/form8k.htm">March&nbsp;2, 2017</A> (solely with respect to Item&nbsp;8.01),
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008117000058/item101_form8kx3162017.htm">March&nbsp;16, 2017</A> (solely with respect to Items&nbsp;1.01 and
3.02), <A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008117000067/form8k_april72017.htm">April&nbsp;10, 2017</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008117000069/form8k_april112017.htm">April&nbsp;17, 2017</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008117000071/v3_ptcform8kxitem201xitem3.htm">April&nbsp;20, 2017</A> (solely with respect to Items&nbsp;2.01,
3.02 and 9.01, as amended on <A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008117000113/form8-ka42017.htm">July&nbsp;3, 2017</A>),
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008117000074/ptcform8-kitem503item901.htm">April&nbsp;21, 2017</A>,
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008117000082/may_8x8kx101x202x203x901.htm">May&nbsp;8, 2017</A> (solely with respect to Items&nbsp;1.01, 2.03
and 9.01), <A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008117000098/a8-k6x1x17.htm">June&nbsp;5, 2017</A> (solely with respect to Item&nbsp;5.02),
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008117000104/a612178-kitem502507.htm">June&nbsp;12, 2017</A> and
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000107008117000115/a8-k8817items202502801.htm">August&nbsp;8, 2017</A> (solely with respect to Item&nbsp;5.02); and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The description of the securities contained in our registration statement on
<A HREF="http://www.sec.gov/Archives/edgar/data/1070081/000110465913049330/a13-6876_78a12b.htm">Form&nbsp;8-A</A> filed under the Exchange Act on June&nbsp;14, 2013,
including any amendment or report filed for the purpose of updating such description. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may request a copy of these filings, at no cost, by writing or telephoning us at the following address or phone number: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>PTC
Therapeutics,&nbsp;Inc.<BR>
100 Corporate Court<BR>
South Plainfield, New Jersey 07080<BR>
(908)&nbsp;222-7000 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=26,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=940369,FOLIO='3',FILE='DISK108:[19ZCA2.19ZCA17702]DA17702A.;10',USER='NDEWIND',CD=';7-AUG-2019;16:19' -->
<A NAME="page_da17702_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A NAME="FLS"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da17702_forward-looking_statements"> </A>
<A NAME="toc_da17702_4"> </A>
<BR></FONT><FONT SIZE=2><B>  FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus and the information incorporated by reference in this prospectus include "forward-looking statements" within the meaning of
Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Exchange Act. All statements contained or incorporated by reference herein, including
statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans, objectives of management and expected market growth, other than
statements of historical facts, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "potential," "will,"
"would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We
cannot guarantee that we actually will achieve the plans, intentions or expectations expressed or implied in our forward-looking statements. There are a number of important factors that could cause
actual results, levels of activity, performance or events to differ materially from those expressed or implied in the forward-looking statements we make. These important factors include our "critical
accounting estimates" described in Part&nbsp;II, Item&nbsp;7 "Management's Discussion and Analysis of Financial Condition and Results of Operations&#151;Critical Accounting Policies and
Significant Judgments and Estimates" of our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2016 and the factors set forth under the caption "Risk Factors" in
Part&nbsp;I, Item&nbsp;1A of our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2016 and under the caption "Risk Factors" in Part&nbsp;II, Item&nbsp;1A of our
Quarterly Reports on Form&nbsp;10-Q for the fiscal quarters ended March&nbsp;31, 2017 and June&nbsp;30, 2017. Although we may elect to update forward-looking statements in the future, we
specifically disclaim any obligation to do so, even if our estimates change, and readers should not rely on those forward-looking statements as representing our views as of any date subsequent to the
date of this prospectus <A NAME="TC"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da17702_the_company"> </A>
<A NAME="toc_da17702_5"> </A>
<BR></FONT><FONT SIZE=2><B>  THE COMPANY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a global biopharmaceutical company focused on the discovery, development, and commercialization of novel medicines using our expertise in
RNA biology. Our internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. We have discovered all of our compounds currently under development using
our proprietary technologies. We plan to continue to develop these compounds both on our own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies.
We have two products, Translarna&#153; (ataluren) and EMFLAZA&#153; (deflazacort). Translarna received marketing authorization from the European Commission in August 2014 for the
treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients age five years and older in the 31 member states of the European Economic Area. EMFLAZA is approved in the United
States for the treatment of Duchenne muscular dystrophy in patients five years and older. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
principal executive offices are located at 100 Corporate Court, South Plainfield, New&nbsp;Jersey&nbsp;07080, and our telephone number is (908)&nbsp;222-7000. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=27,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=935240,FOLIO='4',FILE='DISK108:[19ZCA2.19ZCA17702]DA17702A.;10',USER='NDEWIND',CD=';7-AUG-2019;16:19' -->
<A NAME="page_da17702_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A NAME="CROE"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da17702_consolidated_ratios_of_earnings_to_fixed_charges"> </A>
<A NAME="toc_da17702_6"> </A>
<BR></FONT><FONT SIZE=2><B>  CONSOLIDATED RATIOS OF EARNINGS TO FIXED CHARGES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth our consolidated ratio of earnings to fixed charges for each of the periods indicated. For purposes of
calculating the ratios in the table below, earnings consist of net loss plus fixed charges. Fixed charges include interest expensed and capitalized, amortized premiums, discounts and capitalized
expenses related to indebtedness, an estimate of the interest within rental expense, and preference security dividend requirements of consolidated subsidiaries. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should read this table in conjunction with the consolidated financial statements and notes incorporated by reference in this prospectus. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Six Months<BR>
Ended June&nbsp;30, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fiscal Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2014 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2013 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2012 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated ratios of earnings to fixed charges(1)(2)(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Due
to our losses for the six months ended June&nbsp;30, 2017 and the years ended December&nbsp;31, 2016, 2015, 2014, 2013 and 2012, the ratio coverage was less
than 1:1.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>We
would have needed to generate additional earnings of $46.2&nbsp;million for the six months ended June&nbsp;30, 2017 and $141.5&nbsp;million,
$170.0&nbsp;million, $98.4&nbsp;million, $51.6&nbsp;million and $26.2&nbsp;million for the years ended December&nbsp;31, 2016, 2015, 2014, 2013 and 2012, respectively, to cover our fixed
charges in those periods.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Our
consolidated ratios of earnings to combined fixed charges and preferred stock dividends for the periods indicated above are the same as our consolidated ratios
of earnings to fixed charges set forth above.  </FONT></DD></DL>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=28,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=383105,FOLIO='5',FILE='DISK108:[19ZCA2.19ZCA17702]DA17702A.;10',USER='NDEWIND',CD=';7-AUG-2019;16:19' -->
<A NAME="page_da17702_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A NAME="UOP"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da17702_use_of_proceeds"> </A>
<A NAME="toc_da17702_7"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We intend to use the net proceeds from the sale of any securities offered under this prospectus for general corporate purposes unless otherwise
indicated in the applicable prospectus supplement. General corporate purposes may include research and development costs, the acquisition or licensing of other products, businesses or technologies,
repayment and refinancing of debt, working capital and capital expenditures. We may temporarily invest the net proceeds in a variety of capital preservation instruments, including short-term,
investment grade, interest bearing instruments and U.S. government securities, until they are used for their stated purpose. We have not determined the amount of net proceeds to be used specifically
for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise set forth in a prospectus supplement, we will not receive any proceeds from the sale of common stock by any selling stockholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=29,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=386942,FOLIO='6',FILE='DISK108:[19ZCA2.19ZCA17702]DA17702A.;10',USER='NDEWIND',CD=';7-AUG-2019;16:19' -->
<A NAME="page_da17702_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A NAME="SS"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da17702_selling_stockholders"> </A>
<A NAME="toc_da17702_8"> </A>
<BR></FONT><FONT SIZE=2><B>  SELLING STOCKHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to covering the offering of the securities by us, this prospectus covers the offering for resale of common stock by selling
stockholders. Information about selling stockholders, if any, will be set forth in a prospectus supplement, in an amendment to the registration statement of which this prospectus is a part or in other
filings we make with the SEC under the Exchange Act, which are incorporated by reference. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=30,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=102045,FOLIO='7',FILE='DISK108:[19ZCA2.19ZCA17702]DA17702A.;10',USER='NDEWIND',CD=';7-AUG-2019;16:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dc17702_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="DODEBT"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc17702_description_of_debt_securities"> </A>
<A NAME="toc_dc17702_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF DEBT SECURITIES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may offer debt securities, which may be senior or subordinated. We refer to the senior debt securities and the subordinated debt securities
collectively as debt securities. The following description summarizes the general terms and provisions of the debt securities. We will describe the specific terms of the debt securities and the
extent, if any, to which the general provisions summarized below apply to any series of debt securities in the prospectus supplement relating to the series and any applicable free writing prospectus
that we authorize to be delivered. When we refer to "PTC," "the Company," "we," "our," and "us" in this section, we mean PTC Therapeutics,&nbsp;Inc. excluding, unless the context otherwise requires
or as otherwise expressly stated, our subsidiaries. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may issue senior debt securities from time to time, in one or more series under a senior indenture to be entered into between us and a senior trustee to be named in a prospectus
supplement, which we refer to as the senior trustee. We may issue subordinated debt securities from time to time, in one or more series under a subordinated indenture to be entered into between us and
a subordinated trustee to be named in a prospectus supplement, which we refer to as the subordinated trustee. The forms of senior indenture and subordinated indenture are filed as exhibits to the
registration statement of which this prospectus forms&nbsp;a part. Together, the senior indenture and the subordinated indenture are referred to as the indentures and, together, the senior trustee
and the subordinated trustee are referred to as the trustees. This prospectus briefly outlines some of the provisions of the indentures. The following summary of the material provisions of the
indentures is qualified in its entirety by the provisions of the indentures, including definitions of certain terms used in the indentures. Wherever we refer to particular sections or defined terms of
the indentures, those sections or defined terms are incorporated by reference in this prospectus or the applicable prospectus supplement. You should review the
indentures that are filed as exhibits to the registration statement of which this prospectus forms&nbsp;a part for additional information. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None
of the indentures will limit the amount of debt securities that we may issue. The applicable indenture will provide that debt securities may be issued up to an aggregate principal
amount authorized from time to time by us and may be payable in any currency or currency unit designated by us or in amounts determined by reference to an index. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The senior debt securities will constitute our unsubordinated general obligations and will rank pari passu with our other unsubordinated
obligations. The subordinated debt securities will constitute our subordinated general obligations and will be junior in right of payment to our senior indebtedness (including senior debt securities),
as described under the heading "&#151;Certain Terms of the Subordinated Debt Securities&#151;Subordination." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
debt securities will be our unsecured obligations unless otherwise specified in the applicable prospectus supplement. Any secured debt or other secured obligations will be
effectively senior to the debt securities to the extent of the value of the assets securing such debt or other obligations. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
applicable prospectus supplement and any free writing prospectus will include any additional or different terms of the debt securities or any series being offered, including the
following terms:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the title and type of the debt securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the debt securities will be senior or subordinated debt securities, and, with respect to debt securities issued under the subordinated
indenture, the terms on which they are subordinated; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the aggregate principal amount of the debt securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the price or prices at which we will sell the debt securities; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=31,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=39994,FOLIO='8',FILE='DISK108:[19ZCA2.19ZCA17702]DC17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_dc17702_1_9"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the maturity date or dates of the debt securities and the right, if any, to extend such date or dates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the rate or rates, if any, per year, at which the debt securities will bear interest, or the method of determining such rate or rates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the date or dates from which such interest will accrue, the interest payment dates on which such interest will be payable or the manner of
determination of such interest payment dates and the related record dates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the right, if any, to extend the interest payment periods and the duration of that extension; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the manner of paying principal and interest and the place or places where principal and interest will be payable; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provisions for a sinking fund, purchase fund or other analogous fund, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any redemption dates, prices, obligations and restrictions on the debt securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the currency, currencies or currency units in which the debt securities will be denominated and the currency, currencies or currency units in
which principal and interest, if any, on the debt securities may be payable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any conversion or exchange features of the debt securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether and upon what terms the debt securities may be defeased; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any events of default or covenants in addition to or in lieu of those set forth in the indenture; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the debt securities will be issued in definitive or global form or in definitive form only upon satisfaction of certain conditions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether debt securities will be guaranteed as to payment or performance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if the debt securities of the series or, if applicable, any guarantees will be secured by any collateral and, if so, a general description of
the collateral and the terms and provisions of such collateral security, pledge or other agreements; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other material terms of the debt securities. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
applicable prospectus supplement will also describe any applicable material U.S. federal income tax consequences. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;When
we refer to "principal" in this section with reference to the debt securities, we are also referring to "premium", if any. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may from time to time, without notice to or the consent of the holders of any series of debt securities, create and issue further debt securities of any such series ranking equally
with the debt securities of such series in all respects (or in all respects other than (1)&nbsp;the payment of interest accruing prior to the issue date of such further debt securities or
(2)&nbsp;the first payment of interest following the issue date of such further debt securities). Such further debt securities may be consolidated and form&nbsp;a single series with the debt
securities of such series and have the same terms as to status, redemption or otherwise as the debt securities of such series. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may present debt securities for exchange and you may present debt securities for transfer in the manner, at the places and subject to the restrictions set forth in the debt
securities and the applicable prospectus supplement. We will provide you those services without charge, although you may have to pay any tax or other governmental charge payable in connection with any
exchange or transfer, as set forth in the indenture. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=32,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=436532,FOLIO='9',FILE='DISK108:[19ZCA2.19ZCA17702]DC17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_dc17702_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Debt
securities may bear interest at a fixed rate or a floating rate. Debt securities bearing no interest or interest at a rate that at the time of issuance is below the prevailing
market rate (original issue discount securities) may be sold at a discount below their stated principal amount. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may issue debt securities with the principal amount payable on any principal payment date, or the amount of interest payable on any interest payment date, to be determined by
reference to one or more currency exchange rates, securities or baskets of securities, commodity prices or indices. You may receive a payment of principal on any principal payment date, or a payment
of interest on any interest payment date, that is greater than or less than the amount of principal or interest otherwise payable on such dates, depending on the value on such dates of the applicable
currency, security or basket of securities, commodity or index. Information as to the methods for determining the amount of principal or interest payable on any date, the currencies, securities or
baskets of securities, commodities or indices to which the amount payable on such date is linked. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Certain Terms of the Senior Debt Securities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Covenants</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Unless we indicate otherwise in a prospectus supplement, the senior debt securities will not contain any financial or
restrictive
covenants, including covenants restricting either us or any of our subsidiaries from incurring, issuing, assuming or guaranteeing any indebtedness secured by a lien on any of our or our subsidiaries'
property or capital stock, or restricting either us or any of our subsidiaries from entering into sale and leaseback transactions. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consolidation, Merger and Sale of Assets</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Unless we indicate otherwise in a prospectus supplement, we may not consolidate with or merge
into any
other person, in a transaction in which we are not the surviving corporation, or convey, transfer or lease our properties and assets substantially as an entirety to any person, in either case,
unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the successor entity, if any, is a U.S. corporation, limited liability company, partnership or trust (subject to certain exceptions provided
for in the senior indenture); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the successor entity assumes our obligations on the senior debt securities and under the senior indenture; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> immediately after giving effect to the transaction, no default or event of default shall have occurred and be continuing; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> certain other conditions are met. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Protection in the Event of a Change in Control</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Unless we indicate otherwise in a prospectus supplement with respect to a particular
series of
senior debt securities, the senior debt securities will not contain any provisions that may afford holders of the senior debt securities protection in the event we have a change in control or in the
event of a highly leveraged transaction (whether or not such transaction results in a change in control). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Events of Default</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Unless we indicate otherwise in a prospectus supplement with respect to a particular series of senior debt
securities, the
following are events of default under the senior indenture for any series of senior debt securities:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> failure to pay interest on any senior debt securities of such series when due and payable, if that default continues for a period of
90&nbsp;days (or such other period as may be specified for such series); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> failure to pay principal on the senior debt securities of such series when due and payable whether at maturity, upon redemption, by declaration
or otherwise (and, if specified for such series, the continuance of such failure for a specified period); </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=33,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=987847,FOLIO='10',FILE='DISK108:[19ZCA2.19ZCA17702]DC17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_dc17702_1_11"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> default in the performance of or breach of any of our covenants or agreements in the senior indenture applicable to senior debt securities of
such series, other than a covenant breach which is specifically dealt with elsewhere in the senior indenture, and that default or breach continues for a period of 90&nbsp;days after we receive
written notice from the trustee or from the holders of 25% or more in aggregate principal amount of the senior debt securities of such series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> certain events of bankruptcy or insolvency, whether or not voluntary; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other event of default provided for in such series of senior debt securities as may be specified in the applicable prospectus supplement. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
we indicate otherwise in a prospectus supplement, the default by us under any other debt, including any other series of debt securities, is not a default under the senior
indenture. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an event of default other than an event of default specified in the fourth bullet point above occurs with respect to a series of senior debt securities and is continuing under the
senior indenture, then, and in each such case, either the trustee or the holders of not less than 25% in aggregate principal amount of such series then outstanding under the senior indenture (each
such series voting as a separate class) by written notice to us and to the trustee, if such notice is given by the holders, may, and the trustee at the request of such holders shall, declare the
principal amount of and accrued interest on such series of senior debt securities to be immediately due and payable, and upon this declaration, the same shall become immediately due and payable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an event of default specified in the fourth bullet point above occurs with respect to us and is continuing, the entire principal amount of and accrued interest, if any, on each series
of senior debt securities then outstanding shall become immediately due and payable. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise specified in the prospectus supplement relating to a series of senior debt securities originally issued at a discount, the amount due upon acceleration shall include
only the original issue price of the senior debt securities, the amount of original issue discount accrued to the date of acceleration and accrued interest, if any. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
certain conditions, declarations of acceleration may be rescinded and annulled and past defaults may be waived by the holders of a majority in aggregate principal amount of all the
senior debt securities of such series affected by the default, each series voting as a separate class. Furthermore, subject to various provisions in the senior indenture, the holders of a majority in
aggregate principal amount of a series of senior debt securities, by notice to the trustee, may waive an existing default or event of default with respect to such senior debt securities and its
consequences, except an uncured default in the payment of principal of or interest on such senior debt securities or in respect of a covenant or provision of the senior indenture which cannot be
modified or amended without the consent of the holders of each such senior debt security. Upon any such waiver, such default shall cease to exist, and any event of default with respect to such senior
debt securities shall be deemed to have been cured, for every purpose of the senior indenture; but no such waiver shall extend to any subsequent or other default or event of default or impair any
right consequent thereto. For information as to the waiver of defaults, see "&#151;Modification and Waiver." </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
holders of a majority in aggregate principal amount of a series of senior debt securities may direct the time, method and place of conducting any proceeding for any remedy available
to the trustee or exercising any trust or power conferred on the trustee with respect to such senior debt securities. However, the trustee may refuse to follow any direction that conflicts with law or
the senior indenture, that may involve the trustee in personal liability or that the trustee determines in good faith may be unduly prejudicial to the rights of holders of such series of senior debt
securities not joining in the giving of such direction and may take any other action it deems proper that is not inconsistent with any </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=34,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=77293,FOLIO='11',FILE='DISK108:[19ZCA2.19ZCA17702]DC17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_dc17702_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2>such
direction received from holders of such series of senior debt securities. A holder may not pursue any remedy with respect to the senior indenture or any series of senior debt securities
unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the holder gives the trustee written notice of a continuing event of default; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the holders of at least 25% in aggregate principal amount of such series of senior debt securities make a written request to the trustee to
pursue the remedy in respect of such event of default; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the requesting holder or holders offer the trustee indemnity satisfactory to the trustee against any costs, liability or expense; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the trustee does not comply with the request within 60&nbsp;days after receipt of the request and the offer of indemnity; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> during such 60-day period, the holders of a majority in aggregate principal amount of such series of senior debt securities do not give the
trustee a direction that is inconsistent with the request. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
limitations, however, do not apply to the right of any holder of a senior debt security to receive payment of the principal of and interest, if any, on such senior debt security in
accordance with the terms of such debt security, or to bring suit for the enforcement of any such payment in accordance with the terms of such debt security, on or after the due date for the senior
debt securities, which right shall not be impaired or affected without the consent of the holder. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
senior indenture requires certain of our officers to certify, on or before a fixed date in each year in which any senior debt security is outstanding, as to their knowledge of our
compliance with all covenants, agreements and conditions under the senior indenture. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Satisfaction and Discharge</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;We can satisfy and discharge our obligations to holders of any series of senior debt securities
if:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> we pay or cause to be paid, as and when due and payable, the principal of and any interest on all senior debt securities of such series
outstanding under the senior indenture; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all senior debt securities of such series have become due and payable or will become due and payable within one year (or are to be called for
redemption within one year) and we deposit in trust a combination of cash and U.S. government or U.S. government agency obligations that will generate enough cash to make interest, principal and any
other payments on the debt securities of that series on their various due dates. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
current U.S. federal income tax law, the deposit and our legal release from the senior debt securities would be treated as a taxable event, and beneficial owners of such debt
securities would generally recognize any gain or loss on such senior debt securities. Purchasers of the senior debt securities should consult their own advisers with respect to the tax consequences to
them of such deposit and discharge, including the applicability and effect of tax laws other than the U.S. federal income tax law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Defeasance</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Unless the applicable prospectus supplement provides otherwise, the following discussion of legal defeasance and discharge
and covenant
defeasance will apply to any senior series of senior debt securities issued under the indentures. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal Defeasance</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;We can legally release ourselves from any payment or other obligations on the senior debt securities of any series
(called "legal
defeasance") if certain conditions are met, including the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We deposit in trust for your benefit and the benefit of all other direct holders of the senior debt securities of the same series&nbsp;a
combination of cash and U.S. government or U.S. government </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=35,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=786277,FOLIO='12',FILE='DISK108:[19ZCA2.19ZCA17702]DC17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_dc17702_1_13"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>agency
obligations that will generate enough cash to make interest, principal and any other payments on the senior debt securities of that series on their various due dates. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> There is a change in current U.S. federal income tax law or an IRS ruling that lets us make the above deposit without causing you to be taxed
on the senior debt securities any differently than if we did not make the deposit and instead repaid the senior debt securities ourselves when due. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We deliver to the trustee a legal opinion of our counsel confirming the tax law change or ruling described above. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we ever did accomplish legal defeasance, as described above, you would have to rely solely on the trust deposit for repayment of the debt securities. You could not look to us for
repayment in the event of any shortfall. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Covenant Defeasance</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Without any change of current U.S. federal tax law, we can make the same type of deposit described above and be
released from
some of the covenants in the senior debt securities (called "covenant defeasance"). In that event, you would lose the protection of those covenants but would gain the protection of having money and
securities set aside in trust to repay the senior debt securities. In order to achieve covenant defeasance, we must do the following (among other things):</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We must deposit in trust for your benefit and the benefit of all other direct holders of the senior debt securities of the same series&nbsp;a
combination of cash and U.S. government or U.S. government agency obligations that will generate enough cash to make interest, principal and any other payments on the senior debt securities of that
series on their various due dates. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We must deliver to the trustee a legal opinion of our counsel confirming that under current U.S. federal income tax law we may make the above
deposit without causing you to be taxed on the senior debt securities any differently than if we did not make the deposit and instead repaid the senior debt securities ourselves when due. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we accomplish covenant defeasance, you can still look to us for repayment of the senior debt securities if there were a shortfall in the trust deposit. In fact, if one of the events
of default occurred (such as our bankruptcy) and the debt securities become immediately due and payable, there may be such a shortfall. Depending on the events causing the default, you may not be able
to obtain payment of the shortfall. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Modification and Waiver</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;We and the trustee may amend or supplement the senior indenture or the senior debt securities without the
consent of any
holder:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to comply with the requirements of the SEC in order to effect or maintain the qualification of the indenture under the Trust Indenture Act of
1939, as amended, or the Trust Indenture Act; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to convey, transfer, assign, mortgage or pledge any assets as security for the senior debt securities of one or more series; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to evidence the succession of a corporation, limited liability company, partnership or trust to us, and the assumption by such successor of our
covenants, agreements and obligations under the senior indenture; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to add to our covenants such new covenants, restrictions, conditions or provisions for the protection of the holders, and to make the
occurrence, or the occurrence and continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of default; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to cure any ambiguity, defect or inconsistency in the senior indenture or in any supplemental indenture or to conform the senior indenture or
the senior debt securities to the description of </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=36,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=241205,FOLIO='13',FILE='DISK108:[19ZCA2.19ZCA17702]DC17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_dc17702_1_14"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>senior
debt securities of such series set forth in this prospectus or any applicable prospectus supplement; </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to provide for or add guarantors with respect to the senior debt securities of any series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to establish the form or forms or terms of the senior debt securities as permitted by the senior indenture; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to evidence and provide for the acceptance of appointment under the senior indenture by a successor trustee, or to make such changes as shall
be necessary to provide for or facilitate the administration of the trusts in the senior indenture by more than one trustee; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to add to, delete from or revise the conditions, limitations and restrictions on the authorized amount, terms, purposes of issue,
authentication and delivery of any series of senior debt securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to make any change to the senior debt securities of any series so long as no senior debt securities of such series are outstanding; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to make any change that does not adversely affect the rights of any holder in any material respect. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
amendments and modifications of the senior indenture or the senior debt securities issued may be made, and our compliance with any provision of the senior indenture with respect to
any series of senior debt securities may be waived, with the consent of the holders of a majority of the aggregate principal amount of the outstanding senior debt securities of all series affected by
the amendment or modification (voting together as a single class); provided, however, that each affected holder must consent to any modification, amendment or waiver
that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> extends the final maturity of any senior debt securities of such series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduces the principal amount of on any senior debt securities of such series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduces the rate or extends the time of payment of interest on any senior debt securities of such series; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduces the amount payable upon the redemption of any senior debt securities of such series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes the currency of payment of principal of or interest on any senior debt securities of such series; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduces the principal amount of original issue discount securities payable upon acceleration of maturity or the amount provable in bankruptcy; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> waives an uncured default in the payment of principal of or interest on the senior debt securities (except in the case of a rescission of
acceleration as described above); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> changes the provisions relating to the waiver of past defaults or changes or impairs the right of holders to receive payment or to institute
suit for the enforcement of any payment or conversion of any senior debt securities of such series on or after the due date therefor; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> modifies any of the provisions of these restrictions on amendments and modifications, except to increase any required percentage or to provide
that certain other provisions cannot be modified or waived without the consent of the holder of each senior debt security of such series affected by the modification; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reduces the above-stated percentage of outstanding senior debt securities of such series whose holders must consent to a supplemental indenture
or to modify or amend or to waive certain provisions of or defaults under the senior indenture. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=37,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=333624,FOLIO='14',FILE='DISK108:[19ZCA2.19ZCA17702]DC17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_dc17702_1_15"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
shall not be necessary for the holders to approve the particular form of any proposed amendment, supplement or waiver, but it shall be sufficient if the holders' consent approves the
substance thereof. After an amendment, supplement or waiver of the senior indenture in accordance with the provisions described in this section becomes effective, the trustee must give to the holders
affected thereby certain notice briefly describing the amendment, supplement or waiver. Any failure by the trustee to give such notice, or any defect therein, shall not, however, in any way impair or
affect the validity of any such amendment, supplemental indenture or waiver. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No Personal Liability of Incorporators, Stockholders, Officers, Directors</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;The senior indenture provides that no recourse shall be had
under any
obligation, covenant or agreement of ours in the senior indenture or any supplemental indenture, or in any of the senior debt securities or because of the creation of any indebtedness represented
thereby, against any of our incorporators, stockholders, officers or directors, past, present or future, or of any predecessor or successor entity thereof under any law, statute or constitutional
provision or by the enforcement of any assessment or by any legal or equitable proceeding or otherwise. Each holder, by accepting the senior debt securities, waives and releases all such liability. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concerning the Trustee</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;The senior indenture provides that, except during the continuance of an event of default, the trustee will not
be liable
except for the performance of such duties as are specifically set forth in the senior indenture. If an event of default has occurred and is continuing, the trustee will exercise such rights and powers
vested in it under the senior indenture and will use the same degree of care and skill in its exercise as a prudent person would exercise under the circumstances in the conduct of such person's own
affairs. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
senior indenture and the provisions of the Trust Indenture Act incorporated by reference therein contain limitations on the rights of the trustee thereunder, should it become a
creditor of ours or any of our subsidiaries, to obtain payment of claims in certain cases or to realize on certain property received by it in respect of any such claims, as security or otherwise. The
trustee is permitted to engage in other transactions, provided that if it acquires any conflicting interest (as defined in the Trust Indenture Act), it must eliminate such conflict or resign. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may have normal banking relationships with the senior trustee in the ordinary course of business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unclaimed Funds</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;All funds deposited with the trustee or any paying agent for the payment of principal, premium, interest or additional
amounts in
respect of the senior debt securities that remain unclaimed for two years after the date upon which such principal, premium or interest became due and payable will be repaid to us. Thereafter, any
right of any holder of senior debt securities to such funds shall be enforceable only against us, and the trustee and paying agents will have no liability therefor. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Governing Law</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;The senior indenture and the senior debt securities will be governed by, and construed in accordance with, the internal
laws of the
State of New York. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Certain Terms of the Subordinated Debt Securities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other than the terms of the subordinated indenture and subordinated debt securities relating to subordination or otherwise as described in the
prospectus supplement relating to a particular series of subordinated debt securities, the terms of the subordinated indenture and subordinated debt securities are identical in all material respects
to the terms of the senior indenture and senior debt securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
or different subordination terms may be specified in the prospectus supplement applicable to a particular series. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subordination</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;The indebtedness evidenced by the subordinated debt securities is subordinate to the prior payment in full of all of our
senior
indebtedness, as defined in the subordinated indenture. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=38,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=207936,FOLIO='15',FILE='DISK108:[19ZCA2.19ZCA17702]DC17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_dc17702_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2>During
the continuance beyond any applicable grace period of any default in the payment of principal, premium, interest or any other payment due on any of our senior indebtedness, we may not make any
payment of principal of or interest on the subordinated debt securities (except for certain sinking fund
payments). In addition, upon any payment or distribution of our assets upon any dissolution, winding-up, liquidation or reorganization, the payment of the principal of and interest on the subordinated
debt securities will be subordinated to the extent provided in the subordinated indenture in right of payment to the prior payment in full of all our senior indebtedness. Because of this
subordination, if we dissolve or otherwise liquidate, holders of our subordinated debt securities may receive less, ratably, than holders of our senior indebtedness. The subordination provisions do
not prevent the occurrence of an event of default under the subordinated indenture. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
term "senior indebtedness" of a person means with respect to such person the principal of, premium, if any, interest on, and any other payment due pursuant to any of the following,
whether outstanding on the date of the subordinated indenture or incurred by that person in the future:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all of the indebtedness of that person for money borrowed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all of the indebtedness of that person evidenced by notes, debentures, bonds or other securities sold by that person for money; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all of the lease obligations which are capitalized on the books of that person in accordance with generally accepted accounting principles; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all indebtedness of others of the kinds described in the first two bullet points above and all lease obligations of others of the kind
described in the third bullet point above that the person, in any manner, assumes or guarantees or that the person in effect guarantees through an agreement to purchase, whether that agreement is
contingent or otherwise; and all renewals, extensions or refundings of indebtedness of the kinds described in the first, second or fourth bullet point above and all renewals or extensions of leases of
the kinds described in the third or fourth bullet point above; unless, in the case of any particular indebtedness, renewal, extension or refunding, the instrument creating or evidencing it or the
assumption or guarantee relating to it expressly provides that such indebtedness, renewal, extension or refunding is not superior in right of payment to the subordinated debt securities. Our senior
debt securities constitute senior indebtedness for purposes of the subordinated debt indenture. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=39,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=49339,FOLIO='16',FILE='DISK108:[19ZCA2.19ZCA17702]DC17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_de17702_1_17"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="DOC"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="de17702_description_of_capital_stock"> </A>
<A NAME="toc_de17702_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF CAPITAL STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following description of our capital stock is intended as a summary only. This description is based upon, and is qualified by reference to,
our restated certificate of incorporation, our amended and restated bylaws and applicable provisions of Delaware corporate law. This summary is not complete. You should read our restated certificate
of incorporation and amended and restated bylaws, which are filed as exhibits to the registration statement of which this prospectus forms&nbsp;a part, for the provisions that are important to you. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
authorized capital stock consists of 125,000,000 shares of common stock and 5,000,000 shares of preferred stock. As of August&nbsp;23, 2017, there were 41,389,046 shares of common
stock outstanding and no shares of preferred stock outstanding. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Common Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting Rights</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of
stockholders and do not
have cumulative voting rights. Each election of directors by our stockholders will be determined by a plurality of the votes cast by the stockholders entitled to vote on the election. In general,
except (1)&nbsp;for the election of directors, (2)&nbsp;as described below under "&#151;Provisions of Our Certificate of Incorporation and Bylaws and Delaware Law That May Have
Anti-Takeover Effects&#151;Super-Majority Voting," (3)&nbsp;in the future to the extent that we have two or more classes or series of stock outstanding with separate voting rights and
(4)&nbsp;as otherwise required by law, any matter to be voted on by our stockholders at any meeting is decided by the vote of the holders of a majority in voting power of the votes cast by the
holders of shares of our stock present or represented at the meeting and voting affirmatively or negatively on such matter. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors,
subject to any
preferential dividend rights of outstanding preferred stock. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liquidation and Dissolution</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive
proportionately
all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any of our outstanding preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other Rights</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Holders of our common stock have no preemptive, subscription, redemption or conversion rights. The rights, preferences
and privileges
of holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transfer Agent and Registrar</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;American Stock Transfer&nbsp;&amp; Trust Company,&nbsp;LLC is the transfer agent and registrar for our
common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NASDAQ Global Select Market</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed on The NASDAQ Global Select Market under the symbol "PTCT." </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preferred Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the terms of our certificate of incorporation, our board of directors is authorized to issue shares of preferred stock in one or more
series without stockholder approval, subject to any limitations imposed by the NASDAQ Marketplace Rules. Our board of directors has the discretion to determine the rights, preferences, privileges and
restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. The purpose of authorizing our board of
directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=40,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=877593,FOLIO='17',FILE='DISK108:[19ZCA2.19ZCA17702]DE17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_de17702_1_18"> </A>

<P style="font-family:times;"><FONT SIZE=2>stock,
while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to
acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. Currently, we have no shares of preferred stock outstanding. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we decide to issue any preferred stock pursuant to this prospectus, we will describe in a prospectus supplement the specific terms of the preferred stock, including, if applicable,
the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the title and stated value; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares we are offering; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the liquidation preference per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the purchase price; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the dividend rate, period and payment date, and method of calculation for dividends; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether dividends will be cumulative and, if cumulative, the date from which dividends will accumulate; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the relative ranking and preference of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the procedures for any auction and remarketing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the provisions for a sinking fund; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the provisions for redemption or repurchase and any restrictions on our ability to exercise those redemption and repurchase rights; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the listing of the preferred stock on any securities exchange or market; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the preferred stock will be convertible into our common stock and, if convertible, the conversion price, or how it will be calculated,
and the conversion period; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the preferred stock will be exchangeable into debt securities and, if exchangeable, the exchange price, or how it will be calculated,
and the exchange period; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> voting rights of the preferred stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> preemptive rights; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> restrictions on transfer, sale or other assignment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether interests in the preferred stock will be represented by depositary shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a discussion of any material U.S. federal income tax considerations applicable to the preferred stock; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as to
dividend rights and rights if we liquidate, dissolve or wind up our affairs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
preferred stock could have other rights, including economic rights that are senior to our common stock that could adversely affect the market value of our common stock. The issuance
of the preferred stock may also have the effect of delaying, deferring or preventing a change in control of us without any action by the shareholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=41,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=311426,FOLIO='18',FILE='DISK108:[19ZCA2.19ZCA17702]DE17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_de17702_1_19"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Options and Warrants  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;30, 2017, we had issued and outstanding options to purchase 7,124,052 shares of our common stock at a weighted average
exercise price of $29.33 per share and warrants to purchase (i)&nbsp;7,030 shares of our common stock at an exercise price of $128.00 per share and (ii)&nbsp;130 shares of our common stock at an
exercise price of $2,520.00 per share. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Convertible Notes  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2015, we issued, at par value, $150.0&nbsp;million aggregate principal amount of 3.0% convertible senior notes due 2022, or
Convertible Notes. The Convertible Notes bear cash interest at a rate of 3.0% per year, payable semi-annually on February&nbsp;15 and August&nbsp;15 of each year, beginning on February&nbsp;15,
2016. The Convertible Notes will mature on August&nbsp;15, 2022, unless earlier repurchased or converted. The conversion rate for the Convertible Notes was initially, and remains,
17.7487 shares of our common stock per $1,000 principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $56.34 per share of our common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Effects of Authorized but Unissued Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have shares of common stock and preferred stock available for future issuance without stockholder approval, subject to any limitations
imposed by the listing standards of The NASDAQ Global Select Market. We may utilize these additional shares for a variety of corporate purposes, including for future public offerings to raise
additional capital or facilitate corporate acquisitions or for payment as a dividend on our capital stock. The existence of unissued and unreserved common stock and preferred stock may enable our
board of directors to issue shares to persons friendly to current management or to issue preferred stock with terms that could have the effect of making it more difficult for a third party to acquire,
or could discourage a third party from seeking to acquire, a controlling interest in our company by means of a merger, tender offer, proxy contest or otherwise. In addition, if we issue preferred
stock, the issuance could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Provisions of Our Certificate of Incorporation and Bylaws and Delaware Law That May Have Anti-Takeover
Effects  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delaware Law</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;We are subject to Section&nbsp;203 of the Delaware General Corporation Law. Subject to certain exceptions,
Section&nbsp;203
prevents a publicly held Delaware corporation from engaging in a "business combination" with any "interested stockholder" for three years following the date that the person became an interested
stockholder, unless either the interested stockholder attained such status with the approval of our board of directors, the business combination is approved by our board of directors and stockholders
in a prescribed manner or the interested stockholder acquired at least 85% of our outstanding voting stock in the transaction in which it became an interested stockholder. A "business combination"
includes, among other things, a merger or consolidation involving us and the "interested stockholder" and the sale of more than 10% of our assets. In general, an "interested stockholder" is any entity
or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person. The restrictions contained in
Section&nbsp;203 are not applicable to any of our existing stockholders that owned 15% or more of our outstanding voting stock upon the closing of our initial public offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Staggered Board; Removal of Directors</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation and our bylaws divide our board of directors into three classes
with
staggered three-year terms. In addition, our certificate of incorporation and our bylaws provide that directors may be removed only for cause and only by the affirmative vote of the holders of 75% of
our shares of capital stock present in person or by proxy and entitled to vote. Under our certificate of incorporation and bylaws, any vacancy on our board of directors, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=42,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=355072,FOLIO='19',FILE='DISK108:[19ZCA2.19ZCA17702]DE17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_de17702_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2>including
a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. Furthermore, our certificate of incorporation
provides that the authorized number of directors may be changed only by the resolution of our board of directors. The classification of our board of directors and the limitations on the ability of our
stockholders to remove directors, change the authorized number of directors and fill vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to
acquire, control of our company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder Action; Special Meeting of Stockholders; Advance Notice Requirements for Stockholder Proposals and Director Nominations</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;Our
certificate
of incorporation and our bylaws provide that any action required or permitted to be taken by our stockholders at an annual meeting or special meeting of stockholders may only be taken if it is
properly brought before such meeting and may not be taken by written action in lieu of a meeting. Our certificate of incorporation and our bylaws also provide that, except as otherwise required by
law, special meetings of the stockholders can only be called by our chairman of the board, our president or chief executive officer or our board of directors. In addition, our bylaws establish an
advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our board of directors.
Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors, or by a
stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder's
intention to bring such business before the meeting. These provisions could have the effect of delaying until the next stockholder meeting stockholder actions that are favored by the holders of a
majority of our outstanding voting securities. These provisions also could discourage a third party from making a tender offer for our common stock, because even if it acquired a majority of our
outstanding voting stock, it would be able to take action as a stockholder, such as electing new directors or approving a merger, only at a duly called stockholders meeting and not by written consent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Super-Majority Voting</I></FONT><FONT SIZE=2>.&nbsp;&nbsp;&nbsp;&nbsp;The Delaware General Corporation Law provides generally that the affirmative vote of a majority of the shares
entitled to vote
on any matter is required to amend a corporation's
certificate of incorporation or bylaws, unless a corporation's certificate of incorporation or bylaws, as the case may be, requires a greater percentage. Our bylaws may be amended or repealed by a
majority vote of our board of directors or the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any annual election of directors. In
addition, the affirmative vote of the holders of at least 75% of the votes that all our stockholders would be entitled to cast in any election of directors is required to amend or repeal or to adopt
any provisions inconsistent with any of the provisions of our certificate of incorporation described above. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directors' Liability  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation limits the personal liability of directors for breach of fiduciary duty to the maximum extent permitted by the
Delaware General Corporation Law and provides that no director will have personal liability to us or to our stockholders for monetary damages for breach of fiduciary duty or other duty as a director.
However, these provisions do not eliminate or limit the liability of any of our directors:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for any breach of the director's duty of loyalty to us or our stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for voting or assenting to unlawful payments of dividends, stock repurchases or other distributions; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> for any transaction from which the director derived an improper personal benefit. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=43,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=693481,FOLIO='20',FILE='DISK108:[19ZCA2.19ZCA17702]DE17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_de17702_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
amendment to or repeal of these provisions will not eliminate or reduce the effect of these provisions in respect of any act, omission or claim that occurred or arose prior to such
amendment or repeal. If the Delaware General Corporation Law is amended to provide for further limitations on the personal liability of directors of corporations, then the personal liability of our
directors will be further limited to the greatest extent permitted by the Delaware General Corporation Law. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our certificate of incorporation provides that we must indemnify our directors and officers and we must advance expenses, including attorneys' fees, to our directors and
officers in connection with legal proceedings, subject to very limited exceptions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
maintain a general liability insurance policy that covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as
directors or officers. In addition, we have entered into indemnification agreements with our directors. These indemnification agreements may require us, among other things, to indemnify each such
director for some expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by him in any action or proceeding arising out of his service as one of our directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
of our non-employee directors may, through their relationships with their employers, be insured and/or indemnified against certain liabilities incurred in their capacity as
members of our board of directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=44,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=338482,FOLIO='21',FILE='DISK108:[19ZCA2.19ZCA17702]DE17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_de17702_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2><A NAME="DOD"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="de17702_description_of_depositary_shares"> </A>
<A NAME="toc_de17702_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF DEPOSITARY SHARES    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may, at our option, elect to offer fractional shares of preferred stock, which we call depositary shares, rather than full shares of
preferred stock. If we do, we will issue to the public receipts, called depositary receipts, for depositary shares, each of which will represent a fraction, to be described in the applicable
prospectus supplement, of a share of a particular series of preferred stock. Unless otherwise provided in the prospectus supplement, each owner of a depositary share will be entitled, in proportion to
the applicable fractional interest in a share of preferred stock represented by the depositary share, to all the rights and preferences of the preferred stock represented by the depositary share.
Those rights include dividend, voting, redemption, conversion and liquidation rights. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
shares of preferred stock underlying the depositary shares will be deposited with a bank or trust company selected by us to act as depositary under a deposit agreement between us,
the depositary and the holders of the depositary receipts. The depositary will be the transfer agent, registrar and dividend disbursing agent for the depositary shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary shares will be evidenced by depositary receipts issued pursuant to the deposit agreement. Holders of depositary receipts agree to be bound by the deposit agreement, which
requires holders to take certain actions such as filing proof of residence and paying certain charges. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
summary of terms of the depositary shares contained in this prospectus is not complete. You should refer to the form of the deposit agreement, our certificate of incorporation and
the certificate of designation for the applicable series of preferred stock that are, or will be, filed with the SEC. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends and Other Distributions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The depositary will distribute all cash dividends or other cash distributions, if any, received in respect of the preferred stock underlying the
depositary shares to the record holders of depositary shares in proportion to the numbers of depositary shares owned by those holders on the relevant record date. The relevant record date for
depositary shares will be the same date as the record date for the underlying preferred stock. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
there is a distribution other than in cash, the depositary will distribute property (including securities) received by it to the record holders of depositary shares, unless the
depositary determines that it is not feasible to make the distribution. If this occurs, the depositary may, with our approval, adopt another
method for the distribution, including selling the property and distributing the net proceeds from the sale to the holders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidation Preference  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If a series of preferred stock underlying the depositary shares has a liquidation preference, in the event of the voluntary or involuntary
liquidation, dissolution or winding up of us, holders of depositary shares will be entitled to receive the fraction of the liquidation preference accorded each share of the applicable series of
preferred stock, as set forth in the applicable prospectus supplement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Withdrawal of Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless the related depositary shares have been previously called for redemption, upon surrender of the depositary receipts at the office of the
depositary, the holder of the depositary shares will be entitled to delivery, at the office of the depositary to or upon his or her order, of the number of whole shares of the preferred stock and any
money or other property represented by the depositary shares. If the depositary receipts delivered by the holder evidence a number of depositary shares in excess of the number of depositary shares
representing the number of whole shares of preferred stock to be </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=45,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=1010265,FOLIO='22',FILE='DISK108:[19ZCA2.19ZCA17702]DE17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_de17702_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2>withdrawn,
the depositary will deliver to the holder at the same time a new depositary receipt evidencing the excess number of depositary shares. In no event will the depositary deliver fractional
shares of preferred stock upon surrender of depositary receipts. Holders of preferred stock thus withdrawn may not thereafter deposit those shares under the deposit agreement or receive depositary
receipts evidencing depositary shares therefor. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Redemption of Depositary Shares  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whenever we redeem shares of preferred stock held by the depositary, the depositary will redeem as of the same redemption date the number of
depositary shares representing shares of the preferred stock so redeemed, so long as we have paid in full to the depositary the redemption price of the preferred stock to be redeemed plus an amount
equal to any accumulated and unpaid dividends on the preferred stock to the date fixed for redemption. The redemption price per depositary share will be equal to the redemption price and any other
amounts per share payable on the preferred stock multiplied by the fraction of a share of preferred stock represented by one depositary share. If less than all the depositary shares are to be
redeemed, the depositary shares to be redeemed will be selected by lot or pro rata or by any other equitable method as may be determined by the depositary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
the date fixed for redemption, depositary shares called for redemption will no longer be deemed to be outstanding and all rights of the holders of depositary shares will cease,
except the right to receive the monies payable upon redemption and any money or other property to which the holders of the depositary shares were entitled upon redemption upon surrender to the
depositary of the depositary receipts evidencing the depositary shares. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting the Preferred Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon receipt of notice of any meeting at which the holders of the preferred stock are entitled to vote, the depositary will mail the information
contained in the notice of meeting to the record holders of the depositary receipts relating to that preferred stock. The record date for the depositary receipts relating to the preferred stock will
be the same date as the record date for the preferred stock. Each record holder of the depositary shares on the record date will be entitled to instruct the depositary as to the exercise of the voting
rights pertaining to the number of shares of preferred stock represented by that holder's depositary shares. The depositary will endeavor, insofar as practicable, to vote the number of shares of
preferred stock represented by the depositary shares in accordance with those instructions, and we will agree to take all action that may be deemed necessary by the depositary in order to enable the
depositary to do so. The depositary will not vote any shares of preferred stock except to the extent it receives specific instructions from the holders of depositary shares representing that number of
shares of preferred stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Charges of Depositary  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will pay all transfer and other taxes and governmental charges arising solely from the existence of the depositary arrangements. We will pay
charges of the depositary in connection with the initial deposit of the preferred stock and any redemption of the preferred stock. Holders of depositary receipts will pay transfer, income and other
taxes and governmental charges and such other charges (including those in connection with the receipt and distribution of dividends, the sale or exercise of rights, the withdrawal of the preferred
stock and the transferring, splitting or grouping of depositary receipts) as are expressly provided in the deposit agreement to be for their accounts. If these charges have not been paid by the
holders of depositary receipts, the depositary may refuse to transfer depositary shares, withhold dividends and distributions and sell the depositary shares evidenced by the depositary receipt. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=46,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=214990,FOLIO='23',FILE='DISK108:[19ZCA2.19ZCA17702]DE17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_de17702_1_24"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amendment and Termination of the Deposit Agreement  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The form of depositary receipt evidencing the depositary shares and any provision of the deposit agreement may be amended by agreement between
us and the depositary. However, any amendment that materially and adversely alters the rights of the holders of depositary shares, other than fee changes, will not be effective unless the amendment
has been approved by the holders of a majority of the outstanding depositary shares. The deposit agreement may be terminated by the depositary or us only if:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all outstanding depositary shares have been redeemed; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> there has been a final distribution of the preferred stock in connection with our dissolution and such distribution has been made to all the
holders of depositary shares. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Resignation and Removal of Depositary  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The depositary may resign at any time by delivering to us notice of its election to do so, and we may remove the depositary at any time. Any
resignation or removal of the depositary will take effect upon our appointment of a successor depositary and its acceptance of such appointment. The successor depositary must be appointed within
60&nbsp;days after delivery of the notice of resignation or removal and must be a bank or trust company having its principal office in the United States and having the requisite combined capital and
surplus as set forth in the applicable agreement. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notices  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The depositary will forward to holders of depositary receipts all notices, reports and other communications, including proxy solicitation
materials received from us, that are delivered to the depositary and that we are required to furnish to the holders of the preferred stock. In addition, the depositary will make available for
inspection by holders of depositary receipts at the principal office of the depositary, and at such other places as it may from time to time deem advisable, any reports and communications we deliver
to the depositary as the holder of preferred stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitation of Liability  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither we nor the depositary will be liable if either is prevented or delayed by law or any circumstance beyond its control in performing its
obligations. Our obligations and those of the depositary will be limited to performance in good faith of our and their duties thereunder. We and the depositary will not be obligated to prosecute or
defend any legal proceeding in respect of any depositary shares or preferred stock unless satisfactory indemnity is furnished. We and the depositary may rely upon written advice of counsel or
accountants, on information provided by persons presenting preferred stock for deposit, holders of depositary receipts or other persons believed to be competent to give such information and on
documents believed to be genuine and to have been signed or presented by the proper party or parties. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=47,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=90336,FOLIO='24',FILE='DISK108:[19ZCA2.19ZCA17702]DE17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dg17702_1_25"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="DOPC"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dg17702_description_of_purchase_contracts_and_purchase_units"> </A>
<A NAME="toc_dg17702_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF PURCHASE CONTRACTS AND PURCHASE UNITS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue purchase contracts, including contracts obligating holders to purchase from or sell to us, and obligating us to sell to or purchase
from the holders, a specified number of shares of our common stock, preferred stock or depositary shares at a future date or dates, which we refer to in this prospectus as purchase contracts. The
price per share of common stock, preferred stock or depositary shares and the number of shares of each may be fixed at the time the purchase contracts are issued or may be determined by reference to a
specific formula set forth in the purchase contracts. The purchase contracts may be issued separately or as part of units, often known as purchase units, consisting of one or more purchase contracts
and beneficial interests in debt securities or any other securities described in the applicable prospectus supplement or any combination of the foregoing, securing the holders' obligations to purchase
the common stock, preferred stock or depositary shares under the purchase contracts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
purchase contracts may require us to make periodic payments to the holders of the purchase units or vice versa, and these payments may be unsecured or prefunded on some basis. The
purchase contracts may require holders to secure their obligations under those contracts in a specified manner, including pledging their interest in another purchase contract. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
applicable prospectus supplement will describe the terms of the purchase contracts and purchase units, including, if applicable, collateral or depositary arrangements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=48,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=66630,FOLIO='25',FILE='DISK108:[19ZCA2.19ZCA17702]DG17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_dg17702_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2><A NAME="DOW"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dg17702_description_of_warrants"> </A>
<A NAME="toc_dg17702_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF WARRANTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue warrants to purchase debt securities, common stock, preferred stock or depositary shares. We may offer warrants separately or
together with one or more additional warrants, debt securities, common stock, preferred stock or depositary shares, or any combination of those securities in the form of units, as described in the
applicable prospectus supplement. If we issue warrants as part of a unit, the accompanying prospectus supplement will specify whether those warrants may be separated from the other securities in the
unit prior to the expiration date of the warrants. The applicable prospectus supplement will also describe the following terms of any warrants:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the specific designation and aggregate number of, and the offering price at which we will issue, the warrants; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the currency or currency units in which the offering price, if any, and the exercise price are payable; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the date on which the right to exercise the warrants will begin and the date on which that right will expire or, if you may not continuously
exercise the warrants throughout that period, the specific date or dates on which you may exercise the warrants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the warrants are to be sold separately or with other securities as parts of units; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the warrants will be issued in definitive or global form or in any combination of these forms, although, in any case, the form of a
warrant included in a unit will correspond to the form of the unit and of any security included in that unit; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any applicable material U.S. federal income tax consequences; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the identity of the warrant agent for the warrants and of any other depositaries, execution or paying agents, transfer agents, registrars or
other agents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the proposed listing, if any, of the warrants or any securities purchasable upon exercise of the warrants on any securities exchange; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the designation and terms of any equity securities purchasable upon exercise of the warrants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the designation, aggregate principal amount, currency and terms of any debt securities that may be purchased upon exercise of the warrants; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if applicable, the designation and terms of the debt securities, common stock, preferred stock or depositary shares with which the warrants are
issued and, the number of warrants issued with each security; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if applicable, the date from and after which any warrants issued as part of a unit and the related debt securities, common stock, preferred
stock or depositary shares will be separately transferable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares of common stock, the number of shares of preferred stock or the number of depositary shares purchasable upon exercise of a
warrant and the price at which those shares may be purchased; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if applicable, the minimum or maximum amount of the warrants that may be exercised at any one time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> information with respect to book-entry procedures, if any; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the antidilution provisions of, and other provisions for changes to or adjustment in the exercise price of, the warrants, if any; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any redemption or call provisions; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any additional terms of the warrants, including terms, procedures and limitations relating to the exchange or exercise of the warrants. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=49,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=110821,FOLIO='26',FILE='DISK108:[19ZCA2.19ZCA17702]DG17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_dg17702_1_27"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2><A NAME="FOS"></A> </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dg17702_forms_of_securities"> </A>
<A NAME="toc_dg17702_3"> </A>
<BR></FONT><FONT SIZE=2><B>  FORMS OF SECURITIES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each debt security, depositary share, purchase contract, purchase unit and warrant will be represented either by a certificate issued in
definitive form to a particular investor or by one or more global securities representing the entire issuance of securities. Unless the applicable prospectus supplement provides otherwise,
certificated securities will be issued in definitive form and global securities will be issued in registered form. Definitive securities name you or your nominee as the owner of the security, and in
order to transfer or exchange these securities or to receive payments other than interest or other interim payments, you or your nominee must physically deliver the securities to the trustee,
registrar, paying agent or other agent, as applicable. Global securities name a depositary or its nominee as the owner of the debt securities, depositary shares, purchase contracts, purchase units or
warrants represented by these global securities. The depositary maintains a computerized system that will reflect each investor's beneficial ownership of the securities through an account maintained
by the investor with its broker/dealer, bank, trust company or other representative, as we explain more fully below. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registered Global Securities  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue the registered debt securities, depositary shares, purchase contracts, purchase units and warrants in the form of one or more fully
registered global securities that will be deposited with a depositary or its nominee identified in the applicable prospectus supplement and registered in the name of that depositary or nominee. In
those cases, one or more registered global securities will be issued in a denomination or aggregate denominations equal to the portion of the aggregate principal or face amount of the securities to be
represented by registered global securities. Unless and until it is exchanged in whole for securities in definitive registered form, a registered global security may not be transferred except as a
whole by and among the depositary for the registered global security, the nominees of the depositary or any successors of the depositary or those nominees. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
not described below, any specific terms of the depositary arrangement with respect to any securities to be represented by a registered global security will be described in the
prospectus supplement relating to those securities. We anticipate that the following provisions will apply to all depositary arrangements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ownership
of beneficial interests in a registered global security will be limited to persons, called participants, that have accounts with the depositary or persons that may hold
interests through participants. Upon the issuance of a registered global security, the depositary will credit, on its book-entry registration and transfer system, the participants' accounts with the
respective principal or face amounts of the securities beneficially owned by the participants. Any dealers, underwriters or agents participating in the distribution of the securities will designate
the accounts to be credited. Ownership of beneficial interests in a registered global security will be shown on, and the transfer of ownership interests will be effected only through, records
maintained by the depositary, with respect to interests of participants, and on the records of participants, with respect to interests of persons holding through participants. The laws of some states
may require that some purchasers of securities take physical delivery of these securities in definitive form. These laws may impair your ability to own, transfer or pledge beneficial interests in
registered global securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;So
long as the depositary, or its nominee, is the registered owner of a registered global security, that depositary or its nominee, as the case may be, will be considered the sole owner
or holder of the securities represented by the registered global security for all purposes under the applicable indenture, deposit agreement, purchase contract, warrant agreement or purchase unit
agreement. Except as described below, owners of beneficial interests in a registered global security will not be entitled to have the securities represented by the registered global security
registered in their names, will not receive or be entitled to receive physical delivery of the securities in definitive form and will not be </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=50,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=567348,FOLIO='27',FILE='DISK108:[19ZCA2.19ZCA17702]DG17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_dg17702_1_28"> </A>

<P style="font-family:times;"><FONT SIZE=2>considered
the owners or holders of the securities under the applicable indenture, deposit agreement, purchase contract, purchase unit agreement or warrant agreement. Accordingly, each person owning a
beneficial interest in a registered global security must rely on the procedures of the depositary for that registered global security and, if that person is not a participant, on the procedures of the
participant through which the person owns its interest, to exercise any rights of a holder under the applicable indenture, deposit agreement, purchase contract, purchase unit agreement or warrant
agreement. We understand that under existing industry practices, if we request any action of holders or if an owner of a beneficial interest in a registered global security desires to give or take any
action that a holder is entitled to give or take under the applicable indenture, deposit agreement, purchase contract, purchase unit agreement or warrant agreement, the depositary for the registered
global security would authorize the participants holding the relevant beneficial interests to give or take that action, and the participants would authorize beneficial owners owning through them to
give or take that action or would otherwise act upon the instructions of beneficial owners holding through them. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Principal,
premium, if any, and interest payments on debt securities, and any payments to holders with respect to depositary shares, warrants, purchase agreements or purchase units,
represented by a registered global security registered in the name of a depositary or its nominee will be made to the depositary or its nominee, as the case may be, as the registered owner of the
registered global security. None of us, the trustees, the warrant agents, the unit agents or any other agent of ours, agent of the trustees or agent of the warrant agents or unit agents will have any
responsibility or liability for any aspect of the records relating to payments made on account of beneficial ownership interests in the registered global security or for maintaining, supervising or
reviewing any records relating to those beneficial ownership interests. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that the depositary for any of the securities represented by a registered global security, upon receipt of any payment to holders of principal, premium, interest or other
distribution of underlying securities or other property on that registered global security, will immediately credit participants' accounts in amounts proportionate to their respective beneficial
interests in that registered global security as shown on the records of the depositary. We also expect that payments by participants to owners of beneficial interests in a registered global security
held through participants will be governed by standing customer instructions and customary practices, as is now the case with the securities held for the accounts of customers or registered in "street
name," and will be the responsibility of those participants. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the depositary for any of the securities represented by a registered global security is at any time unwilling or unable to continue as depositary or ceases to be a clearing agency
registered under the Exchange Act, and a successor depositary registered as a clearing agency under the Exchange Act is not appointed by us within 90&nbsp;days, we will issue securities in
definitive form in exchange for the registered global security that had been held by the depositary. Any securities issued in definitive form in exchange for a registered global security will be
registered in the name or names that the depositary gives to the relevant trustee, warrant agent, unit agent or other relevant agent of ours or theirs. It is expected that the depositary's
instructions will be based upon directions received by the depositary from participants with respect to ownership of beneficial interests in the registered global security that had been held by the
depositary. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=51,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=132310,FOLIO='28',FILE='DISK108:[19ZCA2.19ZCA17702]DG17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_dg17702_1_29"> </A>

<P style="font-family:times;"><FONT SIZE=2><A NAME="POD"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dg17702_plan_of_distribution"> </A>
<A NAME="toc_dg17702_4"> </A>
<BR></FONT><FONT SIZE=2><B>  PLAN OF DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We or a selling stockholder may sell securities:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to or through underwriters, brokers or dealers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> through agents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> directly to one or more other purchasers in negotiated sales or competitively bid transactions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> through a block trade in which the broker or dealer engaged to handle the block trade will attempt to sell the securities as agent, but may
position and resell a portion of the block as principal to facilitate the transaction; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> through a combination of any of the above methods of sale. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we may issue the securities as a dividend or distribution or in a subscription rights offering to our existing security holders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
or any selling stockholder may directly solicit offers to purchase securities, or agents may be designated to solicit such offers. We will, in the prospectus supplement relating to
such offering, name any agent that could be viewed as an underwriter under the Securities Act, and describe any commissions that we must pay. Any such agent will be acting on a best efforts basis for
the period of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may be used in connection with any offering of our securities
through any of these methods or other methods described in the applicable prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
distribution of the securities may be effected from time to time in one or more transactions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at a fixed price, or prices, which may be changed from time to time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at market prices prevailing at the time of sale; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at prices related to such prevailing market prices; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at negotiated prices. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
prospectus supplement will describe the method of distribution of the securities and any applicable restrictions. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
prospectus supplement with respect to the securities of a particular series will describe the terms of the offering of the securities, including the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the name of the agent or any underwriters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the public offering or purchase price; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> and the proceeds we will receive from the sales of securities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any discounts and commissions to be allowed or paid to the agent or underwriters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> all other items constituting underwriting compensation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any discounts and commissions to be allowed or re-allowed or paid to dealers; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any exchanges on which the securities will be listed. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any underwriters or agents are utilized in the sale of the securities in respect of which this prospectus is delivered, we will enter into an underwriting agreement or other agreement
with them at the time of sale to them, and we will set forth in the prospectus supplement relating to such offering the names of the underwriters or agents and the terms of the related agreement with
them. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=52,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=89584,FOLIO='29',FILE='DISK108:[19ZCA2.19ZCA17702]DG17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_dg17702_1_30"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a dealer is utilized in the sale of the securities in respect of which the prospectus is delivered, we or a selling stockholder will sell such securities to the dealer, as principal.
The dealer may then resell such securities to the public at varying prices to be determined by such dealer at the time of resale. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we offer securities in a subscription rights offering to our existing security holders, we may enter into a standby underwriting agreement with dealers, acting as standby
underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase on a standby basis. If we do not enter into a standby underwriting arrangement, we may
retain a dealer-manager to manage a subscription rights offering for us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Remarketing
firms, agents, underwriters, dealers and other persons may be entitled under agreements which they may enter into with us to indemnification by us against certain civil
liabilities, including liabilities under the Securities Act, and may be customers of, engage in transactions with or perform services for us in the ordinary course of business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may pay expenses incurred with respect to the registration of the shares of common stock owned by any selling stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
so indicated in the applicable prospectus supplement, we or any selling stockholder will authorize underwriters or other persons acting as our agents to solicit offers by certain
institutions to purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the prospectus supplement. Each contract will be for an
amount not less than, and the aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in the prospectus supplement. Institutions
with whom the contracts, when authorized, may be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other
institutions, but shall in all cases be subject to our approval. Delayed delivery contracts will not be subject to any conditions except that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the purchase by an institution of the securities covered under that contract shall not at the time of delivery be prohibited under the laws of
the jurisdiction to which that institution is subject; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if the securities are also being sold to underwriters acting as principals for their own account, the underwriters shall have purchased such
securities not sold for delayed delivery. The underwriters and other persons acting as our agents will not have any responsibility in respect of the validity or performance of delayed delivery
contracts. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
agents, underwriters and dealers, and their associates and affiliates may be customers of, have borrowing relationships with, engage in other transactions with, or perform
services, including
investment banking services, for us or one or more of our respective affiliates or any selling stockholder in the ordinary course of business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to facilitate the offering of the securities, any underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the securities or any other
securities the prices of which may be used to determine payments on such securities. Specifically, any underwriters may overallot in connection with the offering, creating a short position for their
own accounts. In addition, to cover overallotments or to stabilize the price of the securities or of any such other securities, the underwriters may bid for, and purchase, the securities or any such
other securities in the open market. Finally, in any offering of the securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allowed to an
underwriter or a dealer for distributing the securities in the offering if the syndicate repurchases previously distributed securities in transactions to cover syndicate short positions, in
stabilization transactions or otherwise. Any of these activities may stabilize </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=53,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=499674,FOLIO='30',FILE='DISK108:[19ZCA2.19ZCA17702]DG17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_dg17702_1_31"> </A>

<P style="font-family:times;"><FONT SIZE=2>or
maintain the market price of the securities above independent market levels. Any such underwriters are not required to engage in these activities and may end any of these activities at any time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
Rule&nbsp;15c6-1 of the Exchange Act, trades in the secondary market generally are required to settle in two business days, unless the parties to any such trade expressly agree
otherwise. The applicable prospectus supplement may provide that the original issue date for your securities may be more than two scheduled business days after the trade date for your securities.
Accordingly, in such a case, if you wish to trade securities on any date prior to the second business day before the original issue date for your securities, you will be required, by virtue of the
fact that your securities initially are expected to settle in more than two scheduled business days after the trade date for your securities, to make alternative settlement arrangements to prevent a
failed settlement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
comply with the securities laws of some states, if applicable, the securities may be sold in such jurisdictions only through registered or licensed brokers or dealers. In addition, in
some states the securities may not be sold unless they have been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
securities may be new issues of securities and may have no established trading market. The securities may or may not be listed on a national securities exchange. We can make no
assurance as to the liquidity of or the existence of trading markets for any of the securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=54,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=42048,FOLIO='31',FILE='DISK108:[19ZCA2.19ZCA17702]DG17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<A NAME="page_dg17702_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2><A NAME="LM"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dg17702_legal_matters"> </A>
<A NAME="toc_dg17702_5"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless the applicable prospectus supplement indicates otherwise, the validity of the securities in respect of which this prospectus is being
delivered will be passed upon by Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP. <A NAME="EXP"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dg17702_experts"> </A>
<A NAME="toc_dg17702_6"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm, has audited our consolidated financial statements included in
our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2016, as set forth
in their reports, which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on
Ernst&nbsp;&amp; Young&nbsp;LLP's reports, given on their authority as experts in accounting and auditing. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
financial statements of the Emflaza Business as of and for the years ended December&nbsp;31, 2016 and 2015, incorporated in this prospectus by reference from the Current Report on
Form&nbsp;8-K/A dated July&nbsp;3, 2017 of PTC Therapeutics, Inc, have been audited by Deloitte&nbsp;&amp; Touche&nbsp;LLP, independent auditors, as stated in their report (which report expresses
an unmodified opinion and includes an emphasis-of-matter paragraph relating to the allocation of certain assets, liabilities, expenses, and income that have historically been held at the Marathon
Pharmaceutical Holdings,&nbsp;LLC corporate level but which are specifically identifiable or attributable to the Emflaza Business), which is incorporated herein by reference. Such financial
statements have been so incorporated in reliance upon the report of such firm given upon their authority as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=55,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=273935,FOLIO='32',FILE='DISK108:[19ZCA2.19ZCA17702]DG17702A.;4',USER='JTAYLORA',CD=';6-AUG-2019;13:14' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg17701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g243370.jpg" ALT="LOGO" WIDTH="180" HEIGHT="93">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Up to $125,000,000  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="47%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="47%" ALIGN="CENTER" >


 </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> PROSPECTUS SUPPLEMENT  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="47%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="47%" ALIGN="CENTER" >


  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=5><B>Cantor</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=5>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-18pt;"><FONT SIZE=5><B> </B></FONT><FONT SIZE=5><B> RBC Capital Markets</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=56,EFW="2239427",CP="PTC THERAPEUTICS, INC.",DN="1",CHK=454751,FOLIO='blank',FILE='DISK106:[19ZCA1.19ZCA17701]HO17701A.;13',USER='CHE106812',CD=';7-AUG-2019;12:19' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g243370.jpg
<DESCRIPTION>G243370.JPG
<TEXT>
begin 644 g243370.jpg
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MIT>H40'KHR;R;1. ]^70@ _3K\8W/V#9A8K>)S'BJ37.( 5&/R/2GRIA$>@
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M:M&;-!-LT:MFZ1$6[9LW2*1)!LW1331;H)%*FBBFFDF4I"%*']6C1H#1HT:
MTEM[:'M+BK[LZP-N_AX9J:YX"RTCC6TS"8J).U,69B8O"MTGAB%%-XA$9(@*
MT6-37$OP1[1+';F+\:N55TG6DCVC6HQERX6]^#"2:HN0B,9UJWL3*E 3-9.G
M90HEA9ND1$! JJ9F2A 'KOPJ&*42B/>F1&^U2.]B[WGRN1=MFX/91;9M9^\V
M]6V(R?BUF[,8YV6-LLKR*-IA8XQE!ZCH'(L2XF12!,"MW%Z5Z-X5B $W10 !
M0X!Z <P!^+L>M-(^R!Y/DJ/R^0=,:N5"L,T;>LV421:^,Q45S5Z.ALJ,%CD
MP%.JW6H"I$C& PD(Y7Z /&)@"K)HT:- :-&CT]=!J5YW?P/O(;^;+?/V1^HN
MBG\HI^6;]X=6;><6RP\_Q%<EC*(=IOC5K;S>H2660,11LA, SB'KJ,*L0QBJ
M/(]!VU"11#HS)9PFV6 K@JJ:<9-0!]XIZ?YYOG#_ %A^O05@?9' [X;L=]B;
MRSIN ZZ,8.O^=[7R\A#R[\^OI$1]1'3./A*(="'B#Z#")@_081TL?[(W^!OQ
MY_[Z9_\ _M[73.6@/3TT:-&@\3>@?E$_?+J'+R7?A%=^/YXVY7^N*WZN-&]
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M2T.&X*/*AD&M@L9]%O6JY7"4=,E25KUH9H!+UR3D8]8JI<[P.00[ Y1#Z0,
MA^D!U!HPGGS-^VV]1V4,!97R'AO($4446-RQK;)JGSQ&QE4U5F"LC".VAWL8
MX412^+C'OQ4<[!,I7+54H &MP=5]ICYL*G$!#-=[%@F$"$]VB[M>+L*6B8(7
MP^$/%,R^.EY!P</7WKI9=4QNS&.8?,0L)^\(/?1@,(==@4?$(=CT'8%[$//Z
MM?BT>-'[=-VQ=-WC57Q^Z<-5TG*"GNSF2/X%D#J)'\"A#IG\)Q\)R&(/1BB
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MW+.X]P>$Q!@6+QA'/SHG^$);,RW*/E0*BN8HI"Z;5G&DN"I"&!4C>4)Z)K&
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MB@1J9FW0UQ#Q<<E!0,8VP'>:!2E,8W6VC,)C=% 3#X2EJ(F,;H/O2E 3&'H
M 1$-7!_"'TF_WS_\6CPA])O]\_\ Q:!2;A^XN,Z<2_%?DK-M5J46WY%,X0E;
MR3;8:?QT_P HR%4I[-^P5J.W\*M!SU5FE9*/B9.0G[D6*G$5&]XD'+9P26:U
M:/ NVG%NYK?M*;HJKAR^82B2X>;9^S+6+1FIMC"\P#"Q8<B:?EN*Q$[@%7-G
MDXV!NA\EXC=3=\FY)%U49*AWS&;6II)25I1?%VY=?-^SR_9HZ_OV/]_G_OT&
+@ ] [^C1HT:#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g337856.jpg
<DESCRIPTION>G337856.JPG
<TEXT>
begin 644 g337856.jpg
M_]C_X  02D9)1@ ! 0$!K@&N  #__@ Y35),3%]'4D%02$E#4SI;4%1#7U1(
M15)!4$555$E#4U])3D-=4%1#7U1(15)?2U],3T=/+D504__; $,  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( %
MJ0,!(@ "$0$#$0'_Q  ?   !! (# 0$            +  <)"@$( P4& @3_
MQ !-$   !@(! @0# 0D,!0T    ! @,$!08'" D $0H2$R$4,5$5%CE!87%X
M@;&W&"(H,CA8<I&7H;+6%QHC)]$D,S='2%-55E=WE+/P_\0 %0$! 0
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M]ILW!7;*F[7X3IUCCK:Q8BFBX7KV38.)@INXPAC#Z2DW4,BR;8RYC>5\"X&
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M,QA';+6?,, \583&+\^8AO;%RBIZ1R*UF_P$H<@G[#V361;JH*^P]TE#E$!
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M[_A[]QZ(6^-)WOCXRCZ_<>-,G?-/6B70V,S4S8.6QO@ZK!EF*UB:N2Q2>JJ
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M2Q5QRZ]88S[CO'LSB3"MUQY:GLYAY.XSE4M4Y<Z\-BBXV?FX9PU2=I2$NO\
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966FO^[$G_@\M_P#$/_PZ)6/MLL]8\V?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
